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Abstract 
Background. Endocrine disruptors (EDC) are exogenous compounds that mimic the 
action of natural hormones and alter the normal endocrine system. Life-long chronic 
exposure to Bisphenol A (BPA), a putative EDC, has been linked with risk of metabolic 
disorders in epidemiological studies.  
Objectives. The aim was to study the human health effects of exposure to BPA, using an 
integrated approach combining environmental epidemiology and toxicology.   
Methods. Urinary levels of BPA exposure were measured in participants of the 
InChianti longitudinal study, a representative population-based study of Italian adults, at 
the Baseline (1998-00) and nine years later (3rd Wave, 2007-09). Hormones levels and 
the gene expression of specific target genes were the end points considered. Results 
were validated in laboratory studies on a human leukemic T-cell line (Jurkat cells).  
Results. In general, urinary BPA (uBPA) concentrations were higher among men and 
younger respondents, and within subjects uBPA concentrations were correlated (r=0.58; 
p=0.013, model adjusted for age, sex, urinary creatinine).  
At baseline, uBPA concentration were associated with higher total testosterone 
concentrations in men (β = 0.05; 95% CI, 0.02–0.08). In the 3rd wave, gene expression 
analysis revealed positive associations between uBPA concentrations and ESR2 
(estrogen receptor beta) expression (β=0.18; 95% CI: 0.04, 0.32) and ESRRA (estrogen 
related receptor alpha) expression (β= 0.17; 95% CI: 0.02, 0.32).  
In a following in vitro study, BPA exposure (0.001-1 micro molar) led to enhanced 
expression of ESRRA and ESR2 in Jurkat cells over a period of 72 hours. 
Conclusions. Results indicate that BPA is bioactive in the human body and is able to 
alter circulating hormone concentrations and estrogen receptor/estrogen-related receptr 
gene expression. In particular, given the role of ERRα as a major control point for 
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oxidative metabolism and heart development, this research provides indications on the 
possible molecular mechanisms of action of BPA in metabolic diseases.  
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1. Introduction 
1.1 Endocrine Disruptors Compounds (EDC). 
The term Endocrine Disruptors Compounds (EDC) was firstly agreed in 1991 by a 
group of scientist who gathered at the U.S. Wingspread Conference to discuss emerging 
chemically-induced alterations in wildlife populations (Colborn et al. 1993). Evidence 
brought to the meeting suggested that a large number of man-made chemicals, used in a 
variety of industrial and agricultural applications and then released in the environment, 
could mimic the action of endogenous hormones and have the potential to alter the 
endocrine system of animals.  
In particular, hormone-like compounds were discussed which were able to bind to 
hormone nuclear receptors such as the estrogen receptors, androgen receptor, and 
thyroid hormone receptor. Once bound, these so-called EDCs can have an agonist or 
antagonist action on the receptor activity (Swedenborg et al. 2009). 
The effects observed in wildlife animals differed from traditional toxicology endpoints 
which normally focussed on gross changes in morphology, development, mortality, or 
tumor incidence. Early evidence showed that hormone-like compounds could elicit a 
more subtle toxicity and affect sexual differentiation, reproductive function, 
neurobehavioral development, and induce autoimmune diseases (Vandenberg et al. 
2009).  
Most notably, these effects were mainly seen in the offspring of exposed animals rather 
than in the adults (Colborn et al. 1993). Observations on wildlife animals shared 
similarities with studies on the pharmacological agent diethylstilbestrol (DES), a potent 
synthetic estrogen administered to pregnant women from 1948–71 (Colborn et al. 
1996). Whereas women exposed to DES during pregnancy were relatively unharmed, 
their daughters who were exposed in utero (so-called DES daughters) had significantly 
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increased rates of uterine, cervical, and vaginal malformations. Due to these first 
observations, it was hypothesised that EDC exposure should be investigated in 
particular during critical periods of development such as perinatal and in utero 
exposure. 
Moreover, hormone-like compounds were shown to contradict another dogma of 
toxicology: the linear relationship between dose and response. Multiple studies on 
EDCs have shown that the mechanism of EDC action is better described by a non-
monotonic curve: biphasic dose response has been observed  in many different 
endpoints (Vandenberg et al. 2012). As a result, EDC low dose effects are not 
necessarily predicted by high dose exposure studies. This created a lot of controversy, 
scientists suggested that the linear models routinely used for risk assessment purposes 
by government agencies should be rejected and replaced entirely in the study of EDC 
(Vandenberg et al. 2009). Also, given that making predictions about the effects of low 
doses by testing higher doses is not appropriate, the identification of relevant or 
environmentally relevant exposure in laboratory studies became a source of continuous 
debate. 
 
Since the first hypotheses formulated in the 1990s, the study of EDC has evolved and 
included hundreds of compounds, and so has its definition, in the attempt to encompass 
an ever increasing and controversial field of research:  
“An endocrine disruptor is an exogenous substance or mixture that alters function(s) of the 
endocrine system and consequently causes adverse health effects in an intact organism, or its 
progeny, or (sub)populations”(W.H.O. 2002) 
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Despite significant advances in the study of endocrine disruptors in the last two 
decades, this remains a controversial field and therefore in need of more study. 
The initial focus on developmental effects and the importance of perinatal exposure has 
widened in recent years and concerns over adult exposure have grown. The incident of 
Seveso, Italy, in 1976 (Baccarelli et al. 2004) showed how exposure to dioxin could 
affect not just exposed infants or pre-natal fetuses but also adolescents and adults. 
Moreover, recent laboratory and animal studies have shown that a variety of 
environmental EDCs, the so called “obesogens”, can influence human adipogenesis and 
obesity (Grun and Blumberg 2006; Newbold et al. 2007). This may also lead to other 
metabolic syndromes such as type-2 diabetes. The resulting metabolic disruption is not 
necessarily linked to a prenatal exposure, rather to a low chronic lifelong exposure.  
Similarly, studies on oral hormone female contraceptives build on the concern over the 
risk of adult exposure to hormone-like compounds and in particular to estrogenic 
compounds. Initial reports associated the use of oral contraceptives in women with 
breast cancer diagnoses (Calle et al. 1996), ovarian cancer, cervical cancer, and 
cerebrovascular disease (Beral et al. 1999). Another study found higher risk of 
myocardial infarction in women taking oral contraceptives (Tanis et al. 2001). Although 
some of the initial findings have been disputed (Hannaford et al. 2010), this remains 
extremely indicative of the risk of adult exposure to estrogenic compounds. 
 
In such a controversial field of research, the need to combine different expertise in the 
study of EDC and adopt an integrated approach is crucial. Laboratory studies alone have 
not reached conclusive results. The convergence of environmental toxicology and 
molecular epidemiology is necessary to study and predict effects of environmental 
chemicals on human health (Jaffery et al. 2002).  
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The integration with environmental toxicology can provide epidemiology with 
biomarkers and molecular end points needed to assess the effects of environmental 
exposures on health and disease. On the other hand, understanding the mechanism of 
action and the toxic effects of a contaminant through toxicological studies is necessary 
to support scientific conclusions from observational studies. 
 
1.2.1 Bisphenol A: commercial uses, human exposure, and biomonitoring studies. 
Bisphenol A (BPA), 2,2-bis(4-hydroxyphenyl)propane, is a chemical first synthesized 
in  1891 by condensation of two phenol groups and one acetone molecule. Dodds and 
Lawson (1936) were the first to discover BPA’s estrogenic properties while in pursuit of 
a synthetic estrogen compound for pharmaceutical use. The two researchers later 
discovered the powerful estrogenic substance diethylstilbestrol (DES), and the research 
into BPA as a drug was put aside (Dickens 1975). In the late 1940s, chemists realized 
BPA’s potential applications in industry; since then, BPA has been widely used as a 
monomer and plasticizer and is considered one of the world’s highest production 
volume chemicals reaching in 2008 the amount of 5.2 million tons (Geens et al. 2012).  
BPA finds application in a wide variety of domestic products containing polycarbonate 
or epoxy resins. Polycarbonate resins represent the main share of the BPA market and 
are largely used for packaging application. Products such as large refillable water 
bottles (commonly present in workplaces), sports bottles, baby bottles, home food 
containers and flatware contain polycarbonate resins. Epoxy resins are the second 
largest end use for BPA and, as inner coatings of food and beverage cans, help to 
protect metals from rusting and corrosion. Other uses of BPA include the production of 
flame retardants, thermal paper, polyester resins, and polyvinyl chloride (PVC) 
stabilizers used in water main pipes (Bailey and Hoekstra 2011).  
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BPA can migrate from containers and come into contact with the surrounding material, 
mainly because of two different processes: under normal conditions, residuals of the 
BPA manufacturing process, namely incomplete polymerization, can leach from the 
product; alternatively, BPA chemical bonds can be hydrolyzed releasing free BPA after 
brushing, under heat exposure or at an alkaline pH (Kang et al. 2003). It has been shown 
that BPA leaches from baby bottles, drinking and sport bottles, plastic stretch film, food 
cans, and dental sealant (Bailey and Hoekstra 2011; Brede et al. 2003; Brotons et al. 
1995; Kawamura et al. 1999; Olea et al. 1996; Schecter et al. 2010). Until recently, 
ingestion was considered the main route of BPA human exposure (Vandenberg et al. 
2007). Yet, new evidence suggests that exposure through inhalation (e.g. dust) and 
transdermal contact may have more than a negligible contribution to the total body 
burden (Geens et al. 2011; Geens et al. 2012). 
In the last decade, biomonitoring studies have determined the extent of human exposure 
to BPA, particularly in industrialized nations. Detectable levels of BPA have been 
measured mostly in urine and blood/serum samples but also in amniotic fluid, follicular 
fluid, placental tissue, and umbilical cord blood (reviewed in Vandenberg et al. 2007).  
Urine is generally the matrix of choice for biomonitoring studies (Calafat 2011): 
evidences from toxicokinetic studies on non-human primates and humans suggest that 
almost the entire proportion of ingested BPA is excreted through urine (Doerge and 
Fisher 2011; Taylor et al. 2011). There is little evidence of BPA bioaccumulation in the 
body:  BPA metabolism is in fact considered rapid (<24 hours). Once ingested, BPA is 
extensively absorbed from the gastrointestinal tract, converted into a glucuronide 
conjugate, and excreted via the kidneys. Similarly, inhaled and adsorbed BPA is 
excreted through urine but may not undergo such an effective metabolism and remain 
unconjugated (Pottenger et al. 2000). Yet, both conjugated (metabolized) and 
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unconjugated (free) BPA are measured in urine as urinary concentrations of total (free + 
conjugated) BPA.    
Results from biomonitoring studies indicate an almost ubiquitous human exposure, with 
BPA being detected in the urine of more than 90% of subjects in surveys representative 
of the US (Calafat et al. 2008) and Canadian populations (Bushnik et al. 2010). Similar 
or even higher detection rates have been reported in smaller or less representative 
studies carried out in the US or Europe (Cobellis et al. 2009; Galloway et al. 2010; 
Kasper-Sonnenberg et al. 2012; Koch et al. 2012; Mahalingaiah et al. 2008; Meeker et 
al. 2010a; Mendiola et al. 2010; Pirard et al. 2012). Biomonitoring analyses carried out 
in China and Korea reported detectable levels of BPA in 50-75% of the subjects 
enrolled in the studies (He et al. 2009; Hong et al. 2009). However, in a follow-up study 
carried out in seven Asian countries, including China and Korea, BPA was detected in 
more than 90% of the samples (Zhang et al. 2011). 
Internal BPA dose in humans can be estimated also by measuring BPA concentration in 
blood. Contrary to urine analysis, blood analyses normally measure free BPA 
concentrations.  
Vandenberg et al (2010a) reviewed the literature of biomonitoring studies and identified 
the range of total urinary BPA concentrations (1-10 ng of BPA/ml urine, mean range), 
and unconjugated (free) BPA concentration (0.5–2.5 ng/ml).  
 
1.2.2 Bisphenol A: experimental studies. In vitro and in vivo evidence of estrogenicity. 
Despite the early evidence (Dodds and Lawson 1936), BPA was assumed to be 
relatively harmless to human health and it was deemed safe for commercial use: BPA 
estrogenicity was not considered potentially harmful until the study of EDCs took off in 
the ‘90s (Vogel 2009). Since then, BPA has been extensively studied.  
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In 1988, the U.S. Environmental Protection Agency (EPA) established the BPA human 
Tolerable Daily Intake (TDI) using data from carcinogenesis studies on rodents. The 
lowest dose used in the studies was divided by an uncertainty factor of 1000 to 
determine the limit of 50 µg BPA/kg of body weight per day (50 µg/kg/day), considered 
the reference safety dose (Vogel 2009). The European Food Safety Authority (EFSA) 
set the same TDI in 2006 (EFSA Panel on Food additives 2006).    
Like the estrogen hormones, BPA binds to the estrogen receptors (ER). In biochemical 
assays, BPA binds both estrogen receptor alpha (ERα) and beta (ERβ), with 
approximately 10 times higher affinity for ERβ (Kuiper et al. 1998; Matthews et al. 
2001). Still, initially BPA was considered a weak environmental estrogen because its 
efficacy in binding ER is 1.000/10.000-fold less compared with 17β-estradiol, the 
predominant female estrogen hormone (Nagel et al. 1997).  
In the last decade, a high number of experimental studies have questioned the 
assumption of BPA weak estrogenicity. Laboratory animal studies have shown how 
BPA can be physiologically active and cause adverse reproductive and developmental 
effects at low doses of exposure [Reviewed in: Chapin et al. (2008); Richter et al. 
(2007a); Thayer and Belcher (2011); Wetherill et al. (2007)].  
Low dose exposure was initially defined as levels below the TDI (50 µg/kg/day) for in 
vivo animal studies, and below 100 nM BPA concentration for in vitro cell or organ 
culture studies (Wetherill et al. 2007). In light of the indications from biomonitoring 
studies (described in section 1.1.1), the range for low dose exposure experimental 
studies is now considered 1 µg/kg/day for in vivo animal studies, and 1-10nM BPA 
concentration for in vitro cell or organ culture studies.  
The vast interest in this topic is testified by the full list of experimental studies on low 
dose effects of BPA in animals which, in 2005, counted more than 150 peer-reviewed 
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studies (vom Saal and Hughes 2005). Similarly, a few years later a panel of experts 
from the U.S National Toxicology Program (NTP-CERHR), in an attempt to assess the 
entire literature on BPA, included more than 550 studies in their review (Chapin et al. 
2008).  
Initially, in vitro studies showed that BPA is not merely a weak estrogen mimic. BPA 
can interact differently with the estrogen receptors compared to 17β-estradiol (Gould et 
al. 1998), and the different binding in the ligand-domain can cause a different 
recruitment of coactivators required for normal gene expression (Hall and Korach 2002; 
Pennie et al. 1998; Routledge et al. 2000). These initial findings prompted the 
classification of BPA as selective estrogen receptor modulator (SERM) like some 
pharmacological compounds.  
However, other in vitro molecular studies have shown that BPA can interact with a 
number of other nuclear receptor systems, not just the ER. BPA has been reported to 
bind to the androgen receptor (AR) showing an anti-androgenic activity (Lee et al. 
2003; Xu et al. 2005). Another study reported an opposite, agonist, effect on AR 
suggesting that BPA action can be tissue-specific (Richter et al. 2007b). Moreover, 
other studies have shown BPA to bind to the thyroid hormone receptor (Moriyama et al. 
2002); the aryl hydrocarbon receptor (Bonefeld-Jørgensen et al. 2007); peroxysome 
proliferator-activated receptor gamma (PPARγ) (Kwintkiewicz et al. 2010); BPA was 
also reported to bind to G-protein-coupled receptor (GPR30) (Thomas and Dong 2006). 
In addition to nuclear hormone receptor activity, BPA can interact with non-classic ER 
systems: BPA shows a high binding affinity to the estrogen-related receptor-γ (ERRγ) in 
biomolecular studies (Okada et al. 2008; Takayanagi et al. 2006). ERRγ belongs to the 
orphan nuclear receptors subfamily NR3B, which include the three isoforms ERRα, 
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ERRβ and ERRγ. No previous studies have indicated that BPA interacts with the other 
two components of the orphan receptor family, ERRα and ERRβ.  
In addition to these studies, it has been suggested that BPA could elicit its activity 
beyond the traditional nuclear receptor binding activity. A non-genomic mechanism has 
been suggested: BPA can have an impact on cellular physiology through rapid 
signalling mechanisms that are independent of nuclear hormone receptor activity that 
influences later gene expression (Nadal et al. 2000). These effects occur within minutes 
or seconds of exposure and are initiated by membrane-associated receptor systems that 
act to modulate the intracellular signalling (Alonso-Magdalena et al. 2005; Ropero et al. 
2006; Soriano et al. 2012). Yet, these rapid signalling can later interact with the 
traditional nuclear receptor pathways and trigger a genomic response. 
 
Investigation into in vitro molecular BPA action has been paralleled by the observation 
of physiological effect in animal studies and in particular in rodents (reviewed in 
(Chapin et al. 2008; Richter et al. 2007a). Studies on rodents have mainly focused on 
developmental effects after early in utero exposure. The literature in this sense is broad 
and covers studies on different endpoints: behavioural changes, and in particular 
aggression; learning and social interaction; developmental effects on the female 
reproductive system, timing of puberty and mammary gland development; 
developmental effects on the male reproductive system, and in particular sperm viability 
and reproduction (Richter et al. 2007a). 
Other endpoints considered have been breast cancer incidence and effects on immune 
system but no clear evidence has emerged (Vandenberg et al. 2009). 
In addition, other studies looked at BPA exposure and hormones levels. BPA has been 
linked with changes in levels of thyroid hormones in rodents, even though results were 
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inconsistent across studies (Wetherill et al. 2007). Similarly, studies on testosterone 
levels in rodents exposed to BPA showed both negative (Akingbemi et al. 2004), and 
positive (Ramos et al. 2003) correlation.  Exposure to BPA has also been linked with 
effects on metabolism: decreased levels of adiponectin (Hugo et al. 2008); fat tissue 
accumulation (Marmugi et al. 2012); insulin resistance, pancreatic disruption and 
possible onset of diabetes (Alonso-Magdalena et al. 2006; Alonso-Magdalena et al. 
2010; Ropero et al. 2008). 
 
1.2.3 Bisphenol A: observational studies.  Epidemiological evidence and study 
limitations. 
As discussed above, the literature on laboratory in vitro and in vivo BPA studies is 
extensive. Indications of reproductive and developmental effects at low levels of 
exposure prompted requests to re-assess the standards for BPA safety and revise the 
TDI limit (Vogel 2009; vom Saal and Hughes 2005).  
Yet, the evidence brought by experimental studies were not considered conclusive nor 
enough consistent (Chapin et al. 2008; EFSA Panel on Food additives 2006; Melnick et 
al. 2002). In general, the range of doses tested was criticised. Very low dose studies 
were criticised for susceptibility to a range of possible confounders or factors of 
variability that would cause a lack of robustness in the results: sample size, dose range, 
statistical analyses and experimental design received criticisms (Chapin et al. 2008; 
Haseman et al. 2001).  
Moreover, results on rodent studies have been debated for their applicability to human 
risk assessment: the fact that the main BPA excretion route in rodents is through biliary 
excretion, and not urine as in humans, is considered a limitation of the results.  
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Additional elements of controversy and scrutiny were the way BPA was administered to 
caged animals (injected or orally absorbed) and, from a regulatory point of view, the use 
of “good laboratory practice (GLP)” protocols in the research (vom Saal et al. 2012).   
After revising the entire literature, NTP-CERHR considered that there were “some 
concern for effects on the brain, behaviour and prostate gland in foetuses, infants and 
children at current human exposures to BPA” and that “the possibility that Bisphenol A 
may alter human development cannot be dismissed” (Chapin et al. 2008). Also, in 2007 
the U.S. National Institute of Environmental Health Sciences (NIEHS) sponsored a 
meeting with an independent panel of Bisphenol A experts (vom Saal et al. 2007) that, 
among other recommendations, concluded: 
“There is a need for epidemiological studies relating health outcomes to BPA exposure, 
particularly during sensitive periods in development. These studies should be based on 
hypotheses from findings in experimental animals. This will require additional development of 
appropriate biomarkers in animal studies that can be used in epidemiological research.” 
 
Epidemiological studies on the effects of exposure to BPA were very sparse until 
recently. In a recent review, Braun et al. (2011a) have counted 23 peer-reviewed 
scientific publications on BPA and human health; when the authors applied their 
inclusion/exclusion criteria, based on minimum requirements for study quality (sample 
sizes, correct selection and description of control or comparison groups, appropriate 
statistical analyses), only 10 studies were considered relevant.  
Table 1.1 summarize the full list of epidemiology studies published between January 
2008 and December 2012: few studies were published before 2008, generally these 
were based on a very limited number of observations, and issues have been raised 
relatively to the quality of urinary BPA measurements before the development of a 
standardized procedure in 2007 (Calafat 2011; Calafat et al. 2008). 
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As indicated in sections 1.1 of this introduction, the initial studies on EDCs focussed on 
the so-called sensitive window of exposure. For this reason, a number of 
epidemiological studies focused on the association of urinary BPA concentrations with 
developmental outcomes after in utero or childhood exposure.  
Among those, most notably Braun et al. (2009) found that prenatal BPA exposure may 
be associated with externalizing behaviours in 2-year-old female. After gathering more 
data from the same prospective birth cohort study, the same researchers found that 
gestational BPA exposure affected behavioural and emotional regulation domains at 3 
years of age, especially among girls (Braun et al. 2011b). These observational studies 
confirm previous indications from experimental studies where gestational BPA 
exposure was associated with disrupted neurodevelopment in animals. Overall, the 
study by Braun and colleagues could rely on different measurements of both mother and 
child exposure to BPA over a period of 2 years. As I will discuss later in the 
introduction, this represent an important point in the studies of human BPA exposure. 
 Another study investigated if peripubertal BPA exposure in girls could have an effect 
on breast and pubertal development but found no significant results (Wolff et al. 2010). 
Given the high number of participants (n=1151) and the high quality uBPA analysis, it 
would appear that peripubertal period could not be the only critical window of exposure 
for pubertal development.   Similarly, other hypotheses emerging from experimental 
studies were investigated: sexual dysfunction, semen quality and risk of breast cancer 
all received attention (Table 1.1) but reached mixed or little conclusions.  
Few studies investigated the effects of BPA exposure with semen quality in men and 
reached different conclusions. Meeker et al. (2010; 2011) found slightly lower levels, 
though not statistically significant, of sperm concentration, motility, and morphology in 
men (n=190) with high levels of uBPA from an infertility clinic. Because of the 
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relatively low number of patients, relationship between BPA and sperm DNA damage 
could warrants further investigation. An occupational study on BPA exposure found 
much more convincing evidence of an adverse effect of BPA on semen quality (Li et al. 
2011). They compared 218 men with and without BPA exposure in the workplace and 
found more than three times the risk of lowered sperm concentration and lower sperm 
vitality. The study design was cross-sectional and, as discussed later in the introduction, 
this represents a limitation. On the other hand, Mendiola et al. (2010) measured uBPA 
concentrations in partners of pregnant women in four U.S. cities. Unsurprisingly, they 
found that uBPA concentrations were not associated with reproductive function and 
sperm count. The fact that only fertile men were selected represents a limitation for the 
conclusions of this study. 
In recent years, the U.S. National Health and Nutrition Examination Survey (NHANES) 
has emerged as a valuable platform for epidemiological analysis on BPA exposure.  
The NHANES is the American food consumption database program conducted by the 
National Center for Health Statistics (NCHS) and the Centers for Disease Control and 
Prevention (CDC). NHANES surveys are cross-sectional and contain a core set of 
physical examinations, clinical and laboratory tests, and personal interviews. Since 
2003, the design also includes the testing of uBPA concentrations in a subset of 
participants. The great number of participants in these surveys is certainly an important 
factor for the interpretations of the results.   
Using the data from NHANES, Meeker and Ferguson (2011) showed an inverse 
association with altered thyroid hormones in adults and adolescents. As discussed in 
section 1.2.2, these results support previous experimental findings.  
Recent research has reported the investigation of metabolic disruption in adults exposed 
to BPA. An increasing number of studies have associated levels of BPA exposure with 
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the incidence of metabolic syndromes, which include obesity, type-2 diabetes, heart 
disease and hypertension.  
A great deal of interest has been  raised by the analysis of data from the NHANES that 
reported associations of BPA exposure with self-reported diagnosis of cardiovascular 
disease (Odds Ratio, OR, per 1-SD increase in BPA concentration: 1.4, 95% CI 1.2–1.6) 
and diabetes (OR 1.4, 95% CI 1.2–1.6) in a group of adults (aged 20 through 74) 
examined in 2003/04 (Lang et al. 2008). In addition, BPA concentrations were 
associated with clinically abnormal concentrations of the liver enzymes y-
glutamyltransferase (OR 1.3, 95% CI 1.1-1.5) and alkaline phosphatase (OR 1.5, 95% 
CI 1.2-1.8). 
The association with cardiovascular disease was confirmed in the following survey 
(NHANES 2005/06) in which an entirely new set of participant was enrolled (Melzer et 
al. 2010). Similar to the first study, odds ratio for cardiovascular disease was 1.33 (95% 
CI 1.01- 1.75). Associations with diabetes did not reach significance in 2005/06, but 
pooled estimates (2003/04 and 2005/06) remained significant (OR 1.24, 95% CI 1.1-
1.4), similarly with the levels of liver enzymes. 
In both studies the number of participants was elevated (n=1455 in 2003/04 and n=1493 
in 2005/06) to provide sufficient statistical power to detect low-dose effects; the authors 
reported 80% power in detecting an OR of 1.4 (Melzer et al. 2010), and an extensive 
array of sensitivity analyses was performed on the data. Another strong point of the 
studies was the population representativeness of the study sample and the high standard 
and accuracy of analysis recognised in the NHANES surveys.     
 
Despite the high standard of the analyses and the indication of repeated findings, the 
evidence brought by the two epidemiological studies was not considered conclusive. In 
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particular, a set of specific limitations in the two studies was identified (Braun et al. 
2011a; EFSA Panel on Food Contact Materials 2010; Hengstler et al. 2011; Sharpe 
2010).  
First, both studies were based on cross-sectional designs and this was considered 
limiting the interpretability of the studies. Due to the study design no indication on 
causation could be drawn. It was theoretically possible, for example, a reverse 
interpretation of the results: suffering an event of coronary artery disease could lead to a 
change in dietary habits, hence a change in exposure to BPA (Sharpe 2010).  
The second limitation, more importantly, was that in the NHANES surveys uBPA 
concentrations were measured only after the time of CVD and diabetes diagnoses. 
Given the long latency periods of the outcomes considered, it was pointed out that more 
indications were needed on the stability of BPA exposure during the etiological window 
of development for such diseases (Braun et al. 2011a; Hengstler et al. 2011). In other 
words, indications whether a single BPA measurement could be representative of a long 
term exposure or not were needed. In addition to this, another source of uncertainty over 
the estimation of BPA exposure was that, in the NHANES surveys, uBPA was 
measured in single-spot urine specimens. It has been show that values of uBPA 
concentration may vary within the day if measured in single-spot samples (Arakawa et 
al. 2004; Teeguarden et al. 2011; Ye et al. 2011). Within day variability may depend on 
two factors: urine volume production and a variable BPA intake. Variable urine 
production can be adjusted in epidemiological analysis using measure of creatinine 
excretion (Calafat et al. 2005) or urine specific gravity (SG) (Mahalingaiah et al. 2008), 
although even these approaches could present some limitations (Barr et al. 2005). On 
the other hand, a variable BPA intake can produce a spike in urine concentration 
difficult to account for. For this reason, 24-hour urine collection has been recommended 
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in epidemiology studies because it would account for within day variability. Yet, longer 
term measures remain needed in repeated specimens over ideally months and years. 
Third, a risk of misclassification was indicated also for the self-reported diagnoses on 
pre-existing cardiovascular disease and diabetes. It was pointed out that, ideally, a 
medical examination would be more precise than the questionnaire-based survey in 
order to reduce the risk of misclassification (Hengstler et al. 2011). 
Finally, BPA bioactivity in the human body at physiological levels was questioned. 
According to some authors and regulatory agencies, the environmental level of human 
exposure would not permit BPA binding to nuclear receptors and to trigger any 
molecular reaction (EFSA Panel on Food Contact Materials 2010). This is based on the 
consideration that orally absorbed BPA is subject to great first pass metabolism and 
BPA weak affinity for ERs. 
The metabolism of BPA in the human body and the difference between conjugated and 
unconjugated BPA have been introduced previously when discussing biomonitoring 
studies (section 1.1.1). Once entered the body, only free BPA is considered capable of 
estrogenic activity. Glucuronide conjugate BPA has little or no affinity for the ERs 
(Matthews et al. 2001). There are two toxicokinetic studies indicating that BPA is 
rapidly metabolized and excreted, therefore suggesting that BPA is only present in the 
body as glucuronide conjugate (Völkel et al. 2002; Völkel et al. 2005), and these studies 
received a lot of attention from regulatory agencies (Vandenberg et al. 2010b).  
On the other hand, evidence from biomonitoring studies, where free BPA was measured 
in blood samples (as discussed in section 1.1.1), contrast the conclusions reached by 
Volkel and colleagues. These conclusions have been heavily criticised for different 
flaws in the study design (Vandenberg et al. 2010b). Therefore, BPA bioactivity in the 
human body is considered a controversial topic and in need of more study. 
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1.3 Aim of the research. 
The purpose of my research was to join a toxicological approach with observational 
human studies to examining the effects of low dose chronic exposure to BPA. Given all 
the indications emerged from regulatory agencies, I set out to investigate the major 
points of the debate around BPA toxicity and the limitations that could be addressed 
through my research. 
 
In order to do that, I took advantage of the information supplied by a population-based 
longitudinal study, the InChianti study. InChianti is a prospective population-based 
survey, designed by the laboratory of Clinical Epidemiology of the Italian National 
Research Council of Aging (INRCA, Florence, Italy) and carried out in the Chianti 
geographic area of Tuscany, Italy (Ferrucci et al. 2000). This database includes data 
from 1,453 participants (age range 20–102 years) randomly selected from two 
municipalities: Greve in Chianti and Bagno a Ripoli. Data collection started in 
September 1998. Participants were then contacted every three years (2001-03; 2004-06; 
2007-09) for follow-up assessment (see Figure 1.1).  
At the study baseline, participants responded to an extensive initial home interview and 
underwent a complete medical examination. Participants were also requested to collect 
24-hour urine, avoiding any meat and fish consumption during the day and over the 
previous 48 hours.  Blood samples were collected on the same day. Clinical information 
was then obtained by routine laboratory analyses of blood and urine samples. This 
included levels of inflammatory proteins; sex hormones levels; liver enzymes and lipid 
levels; glucose metabolism; and a collection of RNA specimens. During the successive 
waves of the study, information was collected following a similar methodology but for 
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the urine samples that were collected as single-spot in the morning. 
 
For this study, uBPA concentrations were measured in a subset of the urine samples 
collected at Baseline (1998-00) and the 3rd Wave (2007-09). Aliquots of urine samples 
were shipped from Italy and analyzed by the Brixham Environmental Laboratory (BEL) 
(Devon, UK), using state-of-the-technology high-performance liquid chromatography-
isotope dilution tandem mass spectrometry (HPLC-MS/MS), and the analytical method 
adopted by the CDC (Calafat et al. 2008).  
 
Objectives of the research (summarized in Figure 1.2): 
1. To estimate the level of BPA exposure in a large-scale European representative 
population. (Chapter 2) 
2. To investigate associations between uBPA concentration and levels of sex 
hormones in the study participants. Given the indications from experimental 
studies, the study hypothesis was that BPA exposure could alter reproductive 
hormone concentrations measured in serum samples. High quality analysis of 
24-hr uBPA concentrations account for the controversy over BPA and within-
day variability. (Chapter 2) 
3. In addition, RNA specimens collected during the 3rd Wave were used in gene 
expression analysis. A set of specific target genes was identified and levels of 
gene expression were analysed for association with uBPA concentration. The 
study hypothesis was that BPA in vivo bioactivity could be measured through 
gene expression analysis of the nuclear receptors activity in blood cells. 
(Chapter 3) 
4. Following up what emerged from the in vivo analysis, I set out to investigate 
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BPA bioactivity in an in vitro study on a human leukaemic T-cell line (Jurkat 
cells). In this study, I investigated the mechanisms and timing of activation of 
the target genes and explored BPA ability to modulate their expression in a time 
window of 72 hours. (Chapter 4) 
5. I will also present the results of uBPA measured in single-spot urine samples 
collected during the 3rd Wave of InChianti in 2007-09. I have explored the 
association between uBPA concentrations measured in samples collected during 
the 3rd Wave and nine years earlier, at Baseline. I provide indication of 
variability in uBPA measurement over a long period of time in light of the 
controversies over BPA epidemiological findings. I could also draw a 
comparison between uBPA concentrations measured in 24-hours and single-spot 
samples and therefore I will comment on the validity of the two measurements. 
(Chapter 5) 
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Table 1.1 Summary of epidemiological studies examining the association of BPA with human health outcomes (2008-2012). [uBPA] = 
Urinary BPA concentrations. 
Endpoint investigated 
Reference Study 
 
Design N Description 
Developmental effects    
Braun et al. (2009; 2011b) Prospective cohort 249; 
244 
BPA exposure during pregnancy, but not childhood, was associated with 
externalizing behavior in 2/3 yrs girls and confirmed in follow-up study. 
Miao et al. (2011) Cross sectional 153 Occupational exposure to BPA during pregnancy was associated with 
shortened anogenital distance in male offspring.  
Padmanabhan et al. (2008) Cross sectional 40 No association between [uBPA] and birth outcomes. 
Wolff et al. (2008a) Cross sectional 192 No association between [uBPA] and pubertal development. 
Wolff et al. (2008b) Prospective cohort 367 No association between [uBPA] and most birth outcomes. 
Wolff et al. (2010) Prospective cohort 1151 No association between [uBPA] and breast/pubertal development. 
Hormones levels    
Galloway et al. (2010) Cross sectional 715 [uBPA] associated with higher total testosterone concentrations in men. 
Meeker et al. (2010a) Cross sectional 167 [uBPA] associated with estradiol:testosterone ratio (E2:T), follicle-
stimulating hormone (FSH), and thyroid stimulating hormone. 
Meeker and Ferguson (2011) Cross sectional 1346 [uBPA] associated with altered thyroid hormones in adults and 
adolescents (NHANES 2007/08). 
Male reproduction    
Li et al. (2009; 2010) Cross sectional 550; 
427 
Occupational BPA exposure associated with male sexual dysfunction in 
both studies. 
Li et al. (2011) Cross sectional 218 Occupational BPA exposure associated with decreased sperm count. 
Meeker et al. (2010b; 2011) Cross-sectional 190 [uBPA] associated with decreased semen quality and DNA damage. 
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Mendiola et al. (2010) Cross sectional 302 Non significant effect on reproductive function and sperm count. 
Endometriosis    
Cobellis et al.(2009) Case-Control 69 No association between [uBPA] and endometriosis. 
Breast Cancer    
Yang et al. (2009) Case-Control 152 [uBPA]  were higher among cases compared with controls. 
Immune System    
Clayton et al. (2011) Cross sectional 3728 [uBPA] associated with higher cytomegalovirus antibody (NHANES 
2003/06). 
CVD, diabetes, and obesity    
Lang et al. (2008)  Cross sectional 1455 [uBPA] associated with CVD and diabetes (NHANES 2003-04). 
Melzer et al. (2010) Cross sectional 1493 [uBPA] associated with CVD but not with diabetes (NHANES 2005-06). 
Melzer et al. (2012a) Cross sectional 591 [uBPA] higher in those with severe coronary artery stenoses compared to 
those with no vessel disease. 
Melzer et al. (2012b) Case-Control 1919 [uBPA] associated with incident coronary artery disease (CAD). 
Shankar and Teppala (2011) Cross sectional 3967 [uBPA] associated with type-2 diabetes (NHANES 2003/08). 
Silver et al. (2011) Cross sectional 4389 [uBPA] association with type-2 diabetes driven only by data from 2003-
04 NHANES cycle (NHANES 2003/08). 
Carwile and Michels (2011) Cross sectional 2747 [uBPA] associated with general obesity in adults (NHANES 2003/06). 
Trasande et al. (2012) Cross sectional 2838 [uBPA] associated with obesity in children and adolescents (NHANES 
2003/08). 
Wang et al. (2012) Cross sectional 3390 [uBPA] associated with generalized obesity, abdominal obesity, and 
insulin resistance in adult Chinese population. 
Renal function    
You et al. (2011) Cross sectional 2573 [uBPA] decreased with decreasing renal function (NHANES 2003/06.) 
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Figure 1.1 The InChianti study time-table. Urinary Bisphenol A was measured in samples collected at Baseline and nine years later 
(Follow-up 3).  
 
 Baseline  Follow-up 1  Follow-up 2  Follow-up 3  
             
  n= 720            n=253   
             
 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009  
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Figure 1.2 Schematic illustrating the aims of the research. 
 
Aims of the study   Results 
Integrated approach in the study of the effects of 
BPA chronic human exposure 
   
     
 BPA bioactivity in the human body  Changes at Physiological level: sex hormone concentration Chapter 2 
   Changes at Molecular level: nuclear receptors activation Chapter 3 and 4 
     
 Methodological issues investigated  Long term human exposure to BPA: measure of stability Chapter 5 
   Within day variability: 24-hours uBPA measurements Chapter 2 
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 2. Daily Bisphenol A Excretion and Associations with Sex Hormone 
Concentrations: Results from the InChianti Adult Population Study. 
 
2.1 Statement of the candidate's contribution to the co-authored paper. 
The candidate had full access to all of the data in the study and was responsible for the 
statistical analysis: descriptive statistics, data tabulation, analyses of the association 
between uBPA concentration and parameters in the InChianti dataset were carried out 
during the first year of the research programme. Analysis and interpretation of the 
results were discussed with Prof. T. Galloway and Prof. D. Melzer who were 
responsible for the study design and the accuracy of the data analysis. The candidate 
also contributed to the drafting of the Materials and Methods and the Results sections as 
well as to the critical revision of the paper. 
 
  
32 
 
Environmental Health Perspectives • volume 118 | number 11 | November 2010 1603
Research
Bisphenol A (BPA) is a synthetic compound 
that is a suspected endocrine disruptor—a 
compound capable of causing dysfunction to 
hormonally regulated body systems (Talsness 
et al. 2009). BPA is used as a monomer in 
polycarbonate plastics and in the epoxy resins 
that are used to line food and beverage con-
tainers; it is one of the world’s highest pro-
duction volume chemicals (Burridge 2003). 
Widespread and continuous daily exposure 
to BPA is believed to occur primarily through 
the diet (Stahlhut et al. 2009), as well as from 
drinking water, dental sealants, dermal expo-
sure, and inhalation of household dusts. The 
presence of measurable concentrations of 
metabolites has been reported in the urine of 
> 90% of people in population-representative 
samples from across the globe (Calafat et al. 
2008; Vandenberg 2007).
Most studies of the health effects of BPA 
have focused on its well-documented estro-
genic activity, with reports of both estro-
gen agonist (Lee et al. 2003) and androgen 
antagonist activity (Bonefeld-Jørgensen et al. 
2007; Lee et al. 2003; Okada et al. 2008). 
Suppression of aromatase activity has been 
observed in laboratory studies (Bonefeld-
Jørgensen et al. 2007), as has binding to alter-
native nuclear receptors, including the aryl 
hydrocarbon receptor (Kruger et al. 2008) and 
estrogen-related receptor γ, the function of 
which remains unknown (Okada et al. 2008). 
In addition, BPA has been reported to cause 
thyroid hormone disruption (Moriyama et al. 
2002), altered pancreatic beta-cell function 
(Ropero et al. 2008), and obesity- promoting 
effects (Newbold et al. 2008). The poten-
tial for low-dose effects has prompted debate 
on revising the current legislation of recom-
mended safe daily exposure levels (Beronius 
et al. 2010; vom Saal et al. 2007).
Based on the animal and laboratory evi-
dence, we previously hypothesized that higher 
urinary BPA concentrations would be associ-
ated with adverse human health effects. Using 
data from the U.S. National Health and 
Nutrition Examination Survey (NHANES) for 
2003–2004, the first large-scale population-
based epidemiological data on urinary BPA 
concentrations with sufficient power to detect 
low-dose effects, we showed for the first time 
a clear correlation between BPA exposure and 
disease in humans (Lang et al. 2008). Higher 
BPA concentrations in NHANES respondents 
were associated with diagnoses of cardiovas-
cular disease and diabetes but not with other 
common diseases, which suggested specificity 
of the reported findings (Melzer et al. 2008, 
2009). We recently used an entirely new study 
sample from the 2005–2006 NHANES to 
conduct an independent replication of the 
association of BPA and cardiovascular disease 
(Melzer et al. 2010). The results of this repli-
cation indicated that chance was an implau-
sible explanation for our results.
Studies to clarify the mechanisms of these 
associations are clearly a priority. A substan-
tive literature documents the disruption of 
circulating reproductive hormone concentra-
tions after BPA exposures in animal mod-
els (reviewed by Richter et al. 2007; see also 
Bonefeld-Jørgensen et al. 2007; Goodman 
et al. 2009; Talsness et al. 2009). Studies of 
human populations have until now been lim-
ited to very small sample sizes. A significant, 
positive relationship was reported between 
circulating androgen concentrations and 
BPA exposure in a small study of 26 normal 
women and 47 women with ovarian dysfunc-
tion (Takeuchi et al. 2004). More recently, 
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Daily Bisphenol A Excretion and Associations with Sex Hormone 
Concentrations: Results from the InCHIANTI Adult Population Study
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Background: Bisphenol A (BPA) is a high production volume chemical widely used in packaging 
for food and beverages. Numerous studies have demonstrated that BPA can alter endocrine function 
in animals, yet human studies remain limited.
oBjective: We estimated daily excretion of BPA among adults and examined hypothesized associa-
tions with serum estrogen and testosterone concentrations.
Methods: We conducted cross-sectional analyses using data from the InCHIANTI Study, a pro-
spective population-based study of Italian adults. Our study included 715 adults between 20 and 
74 years old. BPA concentrations were measured by liquid chromatography–mass spectrometry in 
24-hr urine samples. The main outcome measures were serum concentrations of total testosterone 
and 17β-estradiol.
results: Geometric mean urinary BPA concentration was 3.59 ng/mL [95% confidence interval (CI), 
3.42–3.77 ng/mL], and mean excretion was 5.63 μg/day (5th population percentile, 2.1 μg/day; 95th 
percentile, 16.4 μg/day). We found higher excretion rates among men, younger respondents, and those 
with increasing waist circumference (p = 0.013) and weight (p = 0.003). Higher daily BPA excretion was 
associated with higher total testosterone concentrations in men, in models adjusted for age and study 
site (p = 0.044), and in models additionally adjusted for smoking, measures of obesity, and urinary crea-
tinine concentrations (β = 0.046; 95% CI, 0.015–0.076; p = 0.004). We found no associations with the 
other serum measures. We also found no associations with the primary outcomes among women, but 
we did find an association between BPA and SHBG concentrations in the 60 premenopausal women.
conclusion: Higher BPA exposure may be associated with endocrine changes in men. The mecha-
nisms involved in the observed cross-sectional association with total testosterone concentrations 
need to be clarified.
key words: endocrine disruption, androgen, antiandrogen, bisphenol A, human biomonitoring, health 
effects, InCHIANTI. Environ Health Perspect 118:1603–1608 (2010). doi:10.1289/ehp.1002367 
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Meeker et al. (2010) studied serum thyroid 
and reproductive hormone levels in 167 men 
recruited through an infertility clinic and 
observed inverse relationships between urinary 
BPA concentrations and the free androgen 
index [ratio of testosterone to sex hormone–
binding globulin (SHBG)], estradiol, and 
thyroid-stimulating hormone. Given these 
findings, we hypothesized that higher urinary 
BPA concentrations would be associated with 
altered reproductive hormone concentrations 
in serum. Because a limitation of previous 
studies has been their reliance on single spot 
urine samples, we based our current analy-
sis on 24-hr urine collections, to provide a 
direct measure of daily excretion rates. We 
selected participants from the InCHIANTI 
study (Aging in the Chianti Area, Tuscany, 
Italy), a representive population-based study 
that was conducted in Chianti, Italy, from 
September 1998 to March 2000. Our analysis 
of the data from this sample provides the first 
report of daily BPA excretion levels in a large 
European cohort.
Materials and Methods
Study population. The InCHIANTI study 
(InCHIANTI 2010) was designed to identify 
risk factors for mid- and late-life morbidity 
and has been described extensively elsewhere 
(Ferrucci et al. 2000).
Briefly, InCHIANTI is a prospective 
 population-based study of a suburban and 
rural town population. City registries were 
used to randomly select adults who were liv-
ing in Greve in Chianti and in Bagno a Ripoli, 
Tuscany, Italy; a multistage sampling method 
was used (296 adults < 65 years old, 533 adults 
65–74 years old, and 102 adults ≥ 75 years old; 
response rate, 91.6% from baseline interview). 
In line with previous work, we have limited 
our analysis here to participants ≤ 74 years 
old. The Instituto Nazionale Riposo e Cura 
Anziani Institutional Review Board provided 
ethical approval for the study. Participants gave 
informed consent, or if they were unable to do 
so, a close relative provided surrogate consent.
Analysis of urinary BPA concentrations. 
Analysis of samples was performed (under 
contract) at the Brixham Environmental 
Laboratory, (Brixham, UK) in compliance 
with Good Laboratory Practice. Because orally 
administered BPA is considered to be rapidly 
and completely excreted, urine is the body fluid 
most appropriate for the biomonitoring assess-
ment of BPA exposure (see Calafat et al. 2005). 
To measure total (free and conjugated) urinary 
concentrations of BPA, we used the methods 
employed by NHANES (Calafat et al. 2008) 
and adopted by the Division of Environmental 
Health Laboratory Sciences, National Center 
for Environmental Health, Centers for Disease 
Control and Prevention to prepare the urine 
samples; we performed the analyses using 
online solid-phase extraction (SPE) coupled 
with high-performance liquid chromatography 
(LC)–isotope dilution tandem mass spectrom-
etry (MS/MS) with peak focusing. Analyses 
where carried out using a commercially 
available, integrated online SPE-LC system 
(Symbiosis Pharma System; Spark Holland 
BV, Emmen, the Netherlands) coupled with a 
triple-quadrupole mass spectrometer equipped 
with a heated electrospray ionization (HESI) 
interface (TSQ Quantum Ultra AM; Thermo 
Scientific, Hemel Hempstead, UK). Two 
major advantages of the Symbiosis Pharma 
system are that a new SPE cartridge is used 
for every analysis and that one SPE cartridge is 
prepared while one is being analyzed. This sys-
tem enabled a 7-min SPE-LC-HESI/MS/MS 
run time for each analysis point. A linear cal-
ibration was obtained from 0.50–100 μg/L 
(R2 > 0.996). The limit of detection (LOD) 
was < 0.50 μg/L BPA, the limit of quantita-
tion was 0.50 μg/L BPA, the lowest calibration 
standard with a signal height: noise height ratio 
> 10 (relative standard deviations < ±20%, all 
other standards < ±15%).
Outcomes. Participants who consented to 
donate a blood sample were asked also to col-
lect the urine for 24 hr in a vessel contain-
ing 3 g boric acid as preservative. During the 
3 days before blood and urine collection, the 
subjects consumed a diet free of meat and fish. 
On the morning of the day before the blood 
samples were drawn, participants urinated and 
flushed away the first voided urine and then 
began the urine collection. During the day 
and night, all the produced urine was saved 
into the plastic bottle stored at room tempera-
ture or in the refrigerator. After 24 hr, bottles 
were weighed and the total volume measured 
in the clinic.
First thing the next morning, after having 
been sedentary for 15 min, fasting blood sam-
ples were collected for routine blood exami-
nation. Aliquots of serum and plasma were 
subsequently prepared and stored at –80°C 
for additional analyses. A 24-hr urine sample 
aliquot (70 mL) was stored at –20°C until 
further analyses.
Testosterone that circulates in the blood 
binds predominantly to protein, with approxi-
mately 40% bound to the high-affinity SHBG 
and 60% to albumin with lower affinity. 
Measurement of serum testosterone typically 
includes estimating total testosterone (free 
plus bound), free testosterone (not protein 
bound), and bioavailable testosterone (not 
SHBG bound).
Total testosterone was assessed through a 
commercial radioimmunological assay (RIA) 
kit (Active Testosterone RIA DSL-4000; 
Diagnostic Systems Laboratories, Webster, 
TX, USA, distributed by Chematil, s.r.l., Angri 
SA, Angri, Italy). The minimum LOD was 
0.08 ng/mL. Intraassay coefficients of variation 
(CVs) for three different concentrations ranged 
from 7.8–9.6%, and interassay CVs ranged 
from 8.4–9.1%. Results were transformed and 
reported as nanograms per milliliter according 
to the manufacturer’s instructions.
SHBG level was measured by RIA (IRMA 
DSL-7400; Diagnostic Products Corp., Los 
Angeles, CA, USA). The analytical sensitivity 
was 3 nmol/L. The intraassay CVs for three 
different concentrations were 1.1–3.7%, and 
interassay CVs were 8.7–11.5%.
Free testosterone was estimated from 
measured total testosterone, SHBG, and albu-
min (4.3 g/dL) using the method described 
by Vermeulen et al. (1999; for a worked 
example, see the International Society for the 
Study of the Aging Male 2010).
Estradiol levels were measured using an 
ultrasensitive RIA (Ultra-sensitive Estradiol RIA 
DSL-4800; Diagnostic Systems Laboratories, 
distributed by Chematil). The theoretical sen-
sitivity was 2.2 pg/mL. Intraassay CVs across 
four different concentrations ranged from 
6.5–8.9%, and interassay CVs ranged from 
7.5–12.2% (at 108.7 pg/mL).
Statistical analyses. Descriptive statistics of 
urinary BPA concentration and serum hormone 
levels were tabulated. We calculated geometric 
means and distribution percentiles of two differ-
ent BPA measures. First, we measured the BPA 
volume concentration (expressed as micrograms 
of BPA/liter of urine). Then, we multiplied 
the BPA concentration by the urine collection 
rate (liters/day), which was measured consider-
ing the urine volume collected in 24 hr, and 
thus obtained the urinary excretion rate of BPA 
(expressed as micrograms/day).
We performed multivariate linear regres-
sion analyses to study the association between 
BPA and a broad range of demographic cova-
riates and possible confounders. Because the 
concentrations of daily BPA excretion were 
not normally distributed, we used natural log 
transformation when BPA was considered the 
dependant variable. BPA values were not trans-
formed when it was considered an explanatory 
variable in serum hormone examination. In all 
analyses, an upper age cutoff was 75 years to 
minimize the problem of comorbidity.
We adjusted our models by selecting dif-
ferent covariates. The variables included in our 
analyses were age, reported in years at the last 
birthday and used as a continuous variable; the 
two municipalities (study sites) where partici-
pants lived; waist circumference (centimeters) 
and weight (kilograms); and body mass index 
(BMI) was calculated as the weight (kilograms) 
divided by the square of height (meters). BMI 
was tested as a continuous variable and as a cat-
egorized dummy variable with subjects divided 
into underweight (< 18.5 kg/m2), recom-
mended weight (18.5–24.9 kg/m2), overweight 
(25.0–29.9 kg/m2), obese I (30.0–34.9 kg/m2), 
and obese II (≥ 35 kg/m2) categories. We also 
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considered smoking status, which appeared to 
be correlated to BPA in unadjusted models.
Urinary creatinine concentration is com-
monly used to adjust within-day variation 
in metabolite analysis from single spot urine 
samples (Barr et al. 2005). Linear regression 
analysis using the outcome (hormone) meas-
ures as the dependant variable was performed 
first considering all the subjects and then con-
sidering men and women separately. Data 
analysis was performed using STATA (version 
10 SE; StataCorp LP, College Station, TX, 
USA); p < 0.05 was considered significant.
Results
The geometric mean urinary concentration of 
BPA was 3.59 ng/mL [95% confidence inter-
val (CI), 3.42–3.77 ng/mL; Table 1]. Based 
on the 24-hr urine collection, the daily excre-
tion rate of BPA had a geometric mean of 
5.63 μg/day but varied widely. The distribution 
was skewed, with a 10th percentile of 2.6 μg/day 
(95% CI, 2.5–2.8 μg/day) and a 90th per-
centile of 11.8 μg/day (95% CI, 10.9–12.7 
μg/day). Daily BPA excretion was lower among 
women than amomg men (p < 0.001 in models 
adjusted for age, sex, and study site) and lower 
with advancing age (p < 0.001). We obtained 
identical results both with and without cor-
rection for creatinine. In models adjusted for 
age, sex, and study site (Table 2), we found 
no associations between daily BPA excretion 
and years of education or smoking status. We 
did find associations with waist circumfer-
ence (β = 0.0062; 95% CI, 0.0016–0.0108; 
p = 0.013) and with weight (β = 0.0064; 95% 
CI, 0.0023–0.0104; p = 0.003).
In models for men, adjusted for age and 
study site, we found no association between 
BPA excretion and 17β-estradiol. However, we 
did find a significant association between daily 
BPA excretion and total testosterone concen-
tration (β = 0.0237; 95% CI, 0.0006–0.0468; 
p = 0.044). In models adjusted for age, study 
site, smoking, BMI, weight, waist, and urinary 
creatinine, the BPA association with total testos-
terone levels was highly significant (β = 0.046; 
95% CI, 0.015–0.076; p = 0.004; Table 3).
To explore further the association with 
testosterone in men, we examined associa-
tions with the derived measure of free tes-
tosterone, based on SHBG concentrations. 
The association between BPA excretion and 
free testosterone narrowly missed significance 
(p = 0.075 in fully adjusted models).
For women, the geometric mean of the 
17β-estradiol concentration was 6.89 pg/mL 
(Table 4), but this varied dramatically by meno-
pause status: 22.4 pg/mL (95% CI, 16.7–30.0 
pg/mL) in the 57 premenopausal women and 
5.3 pg/mL (95% CI, 4.8–5.7 pg/mL) in the 
290 postmenopausal women. In the models 
that tested hormone associations with BPA 
excretion among women (Table 4), we found 
no significant associations for either estradiol 
or total testosterone. Both SHBG concentra-
tion and the derived measure of free testoster-
one showed significant associations with BPA 
excretion in premenopausal women, although 
it should be noted that the method used 
(direct measure of free testosterone by RIA 
and calculation of the free androgen index) 
was not designed for measuring androgen 
Table 1. Geometric mean (GM) and selected population percentiles of urinary BPA concentrations and daily excretion of the study sample.
GM (95% CI)
Percentile (95% CI)
BPA variable n (%) 5th 10th 25th 50th 75th 90th 95th
All
UER (μg/day) 715 5.63 (5.37–5.90) 2.1 (1.9–2.3) 2.6 (2.5–2.8) 3.7 (3.6–3.9) 5.6 (5.1–5.8) 8.3 (7.7–8.7) 11.8 (10.9–12.7) 16.4 (14.0–20.1)
Urinary concentration (ng/mL) 720 3.59 (3.42–3.77) 1.3 (1.2–1.4) 1.6 (1.5–1.7) 2.3 (2.1–2.4) 3.5 (3.3–3.7) 5.4 (5.0–5.9) 8.0 (7.4–9.5) 11.5 (10.3–13.7)
Sex
Male
UER (μg/day) 332 (46.4) 6.26 (5.87–6.68) 2.5 (2.0–2.7) 3.0 (2.6–3.3) 4.3 (3.9–4.6) 6.1 (5.7–6.8) 9.0 (8.3–9.7) 12.5 (11.7–15.4) 16.7 (14.5–23.7)
Urinary concentration (ng/mL) 334 (46.4) 4.02 (3.76–4.31) 1.5 (1.4–1.6) 1.8 (1.6–2.0) 2.4 (2.3–2.7) 3.9 (3.6–4.3) 6.3 (5.7–6.7) 9.8 (8.1–10.9) 13.0 (10.7–14.8)
Female
UER (μg/day) 383 (53.6) 5.14 (4.81–5.49) 2.0 (1.8–2.2) 2.4 (2.2–2.6) 3.5 (3.2–3.7) 4.9 (4.5–5.3) 7.3 (6.7–8.2) 10.7 (9.9–12.3) 14.4 (12.2–20.4)
Urinary concentration (ng/mL) 386 (53.6) 3.25 (3.04–3.47) 1.1 (1.1–1.3) 1.4 (1.3–1.6) 2.1 (2.0–2.3) 3.2 (2.9–3.4) 4.7 (4.4–5.2) 7.2 (6.5–7.8) 11.0 (7.7–14.1)
Age group (years)
20–40
UER (μg/day) 109 (15.2) 6.61 (5.98–7.31) 2.6 (2.3–3.2) 3.2 (2.6–3.8) 4.7 (4.0–5.3) 6.7 (5.8–7.7) 8.9 (8.3–10.9) 12.5 (11.2–16.6) 16.9 (12.6–24.1)
Urinary concentration (ng/mL) 111 (15.4) 4.31 (3.86–4.82) 1.6 (1.2–2.1) 2.1 (1.6–2.3) 3.2 (2.4–3.6) 4.4 (4.0–4.8) 6.0 (5.6–6.8) 8.3 (7.0–12.0) 12.2 (8.4–17.4)
41–65
UER (μg/day) 157 (22.0) 6.69 (6.04–7.40) 2.7 (2.2–3.2) 3.2 (2.8–3.6) 4.6 (4.0–5.0) 6.2 (5.6–6.9) 9.2 (8.1–10.3) 16.1 (11.3–21.3) 23.8 (16.7–40.7)
Urinary concentration (ng/mL) 157 (21.8) 3.95 (3.53–4.42) 1.4 (1.2–1.5) 1.5 (1.4–2.0) 2.4 (2.1–2.8) 3.7 (3.3–4.4) 5.8 (5.1–6.7) 9.6 (7.5–15.3) 16.7 (11.1–22.3)
66–74
UER (μg/day) 449 (62.8) 5.10 (4.80–5.41) 1.9 (1.6–2.1) 2.4 (2.1–2.6) 3.5 (3.1–3.6) 4.9 (4.5–5.3) 7.4 (7.0–8.3) 10.9 (9.9–12.1) 14.2 (12.2–17.1)
Urinary concentration (ng/mL) 452 (62.8) 3.32 (3.12–3.53) 1.2 (1.1–1.3) 1.5 (1.3–1.6) 2.1 (2.0–2.3) 3.2 (2.9–3.4) 4.8 (4.4–5.6) 7.6 (7.0–8.9) 10.7 (9.3–12.8)
Table 2. Geometric means (GMs) of BPA excretion, by covariate status, plus age, sex, and study site 
using adjusted regression estimates of association.
Variable n (%) GM (μg/day) (95% CI) p-Valuea
Education (years)
0 3 (0.4) 4.72 (1.80 to 12.35) (dropped)
1–5 364 (50.9) 5.06 (4.75 to 5.39) —b
6–8 152 (21.3) 6.27 (5.59 to 7.02) 0.071
9–13 123 (17.2) 6.07 (5.46 to 6.75) 0.968
14–19 63 (8.8) 6.99 (5.99 to 8.17) 0.170
≥ 20 10 (1.4) 5.84 (3.82 to 8.94) 0.576
BMI category (kg/m2)
Underweight (BMI 0–18.5) 4 (0.6) 2.74 (1.29 to 5.81) (dropped)
Normal (BMI 18.5–25) 215 (30.1) 5.67 (5.22 to 6.16) —b
Overweight (BMI 25–30) 314 (43.9) 5.84 (5.43 to 6.27) 0.296
Obese I (BMI 30.1–34.9) 138 (19.3) 5.66 (5.04 to 6.34) 0.369
Obese II (BMI ≥ 35) 32 (4.5) 4.85 (3.94 to 5.98) 0.738
Unknown 12 (1.6) 3.46 (2.65 to 4.52) (dropped)
Smoking history
Never 380 (53.2) 3.20 (3.03 to 3.37) —b
Former 171 (23.9) 3.76 (3.50 to 4.05) 0.259
Current 164 (22.9) 3.95 (3.62 to 4.32) 0.773
Continuous measures
Waist circumference (cm) 715 β = 0.0062 (0.0016 to 0.0108) 0.013
Weight (kg) 715 β = 0.0064 (0.0023 to 0.0104) 0.003
Urinary creatinine concentration (mg/dL) 715 β = –0.0012 (–0.0025 to 0.0003) 0.116
aAdjusted for age, sex, and site. bThe base category against which the others are tested.
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concentrations in women, where the concen-
trations involved are at the very lowest LODs 
(Miller et al. 2004; Vermeulen et al. 1999).
Sensitivity analysis. For a sensitivity analy-
sis of our main finding, we examined the rela-
tionship between daily BPA excretion and 
total testosterone levels in men, excluding 
outlier BPA values above 25 μg/day (n = 7 
removed, ranging from 25.29–41.12 μg/day) 
(see Figure 1 for unadjusted model). In fully 
adjusted models as above, BPA excretion per 
day remained associated with total testoster-
one concentrations in men (β = 0.0521; 95% 
CI, 0.0172–0.08703; p = 0.004).
Post hoc analyses for bioavailable testoster-
one showed patterns similar to those reported 
for free testosterone (data not shown). 
Associations with estradiol: testosterone ratios 
were nonsignificant.
Discussion
In this study, we have reported for the first 
time the daily excretion levels of BPA among 
European adults in a large-scale and high-
quality population-based sample. After adjust-
ing for potential confounders, we have shown 
that higher BPA daily excretion was associated 
with an increase in serum total testosterone 
concentration in men.
These results are important because they 
provide the first report, using data from a 
large-scale human population, of associations 
between elevated exposure to BPA and altera-
tions in circulating hormone levels. They also 
illustrate that the extent of exposure to BPA is 
similar in this European urban and rural popu-
lation to exposures seen in the general adult 
population of the United States (Calafat et al. 
2008). Previous studies of the relationship 
between human exposure to BPA and endo-
crine function are sparse and involve reported 
alterations in androgens (gonadotrophins or 
testosterone) in urine or serum in both men 
and women, although the numbers of par-
ticipants were small (Hanaoka et al. 2002; 
Takeuchi and Tsutsumi 2002; Takeuchi et al. 
2004). Hanaoka et al. (2002) studied 42 occu-
pationally exposed male production workers 
and age-matched controls and showed that 
urinary BPA concentrations were inversely 
associated with follicle-stimulating hormone 
(FSH) but not with free testosterone or leuti-
nizing hormone. In a later study of 167 men 
recruited through an infertility clinic (Thuillier 
et al. 2009), BPA concentrations in urine 
were positively associated with both FSH 
and FSH:inhibin ratio and inversely associ-
ated with estradiol:testosterone ratio. Because 
FSH and inhibin B are the two hormones 
considered most predictive of semen quality, 
Thuillier et al. (2009) concluded that BPA 
may have been associated with adverse effects 
on Sertoli cells or their FSH receptors that led 
to altered inhibin B production and reduced 
semen quality. In an animal study, rats 
exposed to BPA in utero did not show signifi-
cant changes in circulating testosterone levels 
in adulthood, which suggests normal function-
ing of Leydig and Sertoli cells (Goodman et al. 
2009). Because estrogens and androgens can 
exert differential effects in function depend-
ing on the cell type and its stage of develop-
ment, the consequences of BPA exposure on 
adult reproductive and somatic tissues merits 
further attention.
Our results showed an association with 
total testosterone concentrations but no sig-
nificant trend in 17β-estradiol levels with 
higher BPA excretion in men. The results 
reported by Meeker et al. (2010) are consis-
tent with those reported here, although the 
positive trend (p = 0.17) between BPA and 
testosterone reported by Meeker et al. (2010) 
did not reach statistical significance in their 
smaller study. Mendiola et al. (2010) reported 
finding no association between urinary BPA 
concentrations and testosterone levels in 
375 male partners of pregnant women; in 
addition to differences in study group, their 
urinary BPA concentrations appear substan-
tially lower than in our study sample.
Plausible explanations for our finding of an 
increase in total testosterone include a reduc-
tion in aromatase activity (Akingbemi et al. 
2004; Huang and Leung 2009; Nativelle-
Serpentini et al. 2003), which would lead to 
a decrease in the conversion of testosterone 
to estradiol. Because BPA has been shown 
to possess antiandrogenic activity (Bonefeld-
Jørgensen et al. 2007; Lee et al. 2003), an 
alternative explanation could be that a block-
ade of androgen-binding sites alters feedback 
control mechanisms that leads to an increase 
in circulating testosterone. Lee et al. (2003) 
showed BPA to affect multiple steps in the 
activation and function of the androgen recep-
tor, including noncompetitive inhibition of 
binding of endogenous androgens, nuclear 
localization, and transactivation, with uncer-
tain consequences for androgen homeostasis. 
In our study, associations with the derived 
measure of free testosterone narrowly missed 
statistical significance.
Alternatively, there could be differential 
effects of BPA on the metabolism of testos-
terone and estrogen. A study of steroid hor-
mone production in rat ovarian cells showed 
that BPA increased both testosterone synthesis 
and the mRNA expression of steroidogenic 
enzymes (Zhou et al. 2008). BPA also sig-
nificantly decreased the activity of enzymes 
involved in the hydroxylation of testosterone, 
including the cytochrome P450 isoforms for 
testosterone 2 α-hydroxylase and testosterone 
6 β-hydroxylase, CYP2C11/6 and CYP3A2/1, 
respectively, in isolated rat livers (Hanioka 
Table 3. Simple and fully adjusted regression models of the associations between BPA (μg/day) and 17β-estradiol and testosterone concentrations for men.
Geometric mean (95% CI)
Age and study-site adjusted Fully adjusteda
Hormone n β-Coefficient (95% CI) p-Value β-Coefficient (95% CI) p-Value
17β-Estradiol (pg/mL) 293 12.89 (12.26 to 13.56) –0.00004 (–0.0086 to 0.0085) 0.992 0.0002 (–0.011 to 0.011) 0.975
Total testosterone (ng/mL) 307 4.55 (4.42 to 4.69) 0.0237 (0.0006 to 0.0468) 0.044 0.046 (0.015 to 0.076) 0.004
SHBG (nmol/mL) 316 80.84 (76.60 to 85.30) –0.0009 (–0.0095 to 0.0076) 0.830 0.0011 (–0.0075 to 0.0096) 0.805
Free testosterone (ng/dL) 316 4.72 (4.50 to 4.95) 0.0081 (–0.0012 to 0.0175) 0.089 0.0088 (–0.0009 to 0.0185) 0.075
aFull models were adjusted for age, study site, smoking, BMI, weight, waist, and urinary creatinine concentration.
Table 4. Simple and fully adjusted regression models of the associations between BPA (μg/day) and 17β-estradiol, testosterone, and SHBG concentrations for women.
Age and study-site adjusted Fully adjusteda
Hormone n Geometric mean (95% CI) β-Coefficient (95% CI) p-Value β-Coefficient (95% CI) p-Value
Premenopause
17β-Estradiol (pg/mL) 57 22.4 (16.7–30.0) –0.026 (–0.066 to 0.014) 0.204 –0.022 (–0.066 to 0.0229) 0.325
Total testosterone (ng/mL) 61 0.69 (0.61–0.77) –0.004 (–0.015 to 0.007) 0.451 –0.007 (–0.018 to 0.004) 0.192
SHBG (nmol/mL) 60 134.3 (111.6–161.5) 0.029 (0.004 to 0.054) 0.024 0.038 (0.013 to 0.063) 0.004
Postmenopause
17β-Estradiol (pg/mL) 290 5.3 (4.8–5.7) –0.002 (–0.010 to 0.005) 0.516 –0.003 (–0.010 to 0.005) 0.448
Total testosterone (ng/mL) 294 0.54 (0.49–0.59) –0.0003 (–0.0036 to 0.0030) 0.871 –0.001 (–0.004 to 0.002) 0.555
SHBG (nmol/mL) 299 105.2 (98.8–112.1) 0.002 (–0.004 to 0.008) 0.541 0.003 (–0.003 to 0.009) 0.272
aFull models adjusted for age, study site, smoking, BMI, weight, waist, and urinary creatinine concentration.
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et al. 1998), both of which could lead to a net 
increase in circulating testosterone. The pos-
sibility that BPA could interfere with the RIA 
used to quantify serum testosterone is unlikely 
given the low cross-reactivity shown by the 
anti-testosterone antibody used in the assay 
and is further discounted by mathematical 
modeling studies showing negligible effects of 
xenoestrogens on the displacement of bound 
hormone and tracer during binding and 
extraction steps in vitro (Heringa et al. 2004).
It is also plausible that an androgenic envi-
ronment leads to alterations in the metabolism 
of BPA, that is, reverse causation. Metabolism 
of BPA in the intestine and liver catalyzed by 
uridine diphosphate-glucuronosyl transferase 
(UGT) yields the major urinary metabolite 
BPA-glucuronide (Teeguarden et al. 2005). 
The level of both UGT activity and transcrip-
tion has been shown to be downregulated by 
androgens (Guillemette et al. 1997; Takeuchi 
et al. 2004), which could result in an increase 
in serum BPA concentration under hyper-
androgenic conditions. However, it is unlikely 
that such metabolic change could alter 24-hr 
urinary BPA excretion in the context of 
repeated ingestion of BPA at the population 
level and the limited increase in testosterone 
concentrations evident in our analysis.
Urinary BPA concentrations have previ-
ously been reported in 100 pregnant European 
women, with 82% of the study population 
showing detectable levels of BPA, median 
concentration 1.2 ng/mL (Ye et al. 2008). 
This concentration is lower than the mean 
value presented here, 3.59 ng/mL (95% CI, 
3.42–3.77 ng/mL), although there are dif-
ferences in age and sex profiles. Most studies 
have reported values from spot urine samples 
with or without correction for creatinine, 
with mean concentrations around 3 ng/mL 
(Dekant and Volkel 2008; Vandenberg et al. 
2010) and 95th percentiles in the range of 11.5 
ng/mL (Ye et al. 2008) to 16 ng/mL (Calafat 
et al. 2005). Here, we used 24-hr urine col-
lection to calculate a mean daily excretion rate 
of 5.63 μg/day (95% CI, 5.67–5.90 μg/day). 
In an earlier Japanese study, Arakawa et al. 
(2004) reported median daily urinary excre-
tions of BPA of 1.3–5.0 μg/day, with a maxi-
mum daily intake of BPA per body weight 
of 0.23 μg/kg/day based on 24-hr urine sam-
ples collected from 36 men; the median daily 
uptake was given as 0.02 μg/kg body weight. 
In controlled, acute human exposure studies, 
peak urinary concentrations of BPA metabo-
lites were 4,500–6,800 μg/L 6 hr after oral 
administration of 60–80 μg/kg body weight. 
Based on these figures and assuming com-
plete and rapid excretion, Dekant and Volkel 
(2008) suggested that a daily excretion rate of 
around 5 μg/L, as seen in the general popula-
tion, indicates ingestion of < 25 μg of BPA in 
the hours prior to sampling (the maximum 
daily reference dose is 50 μg/kg/day). However, 
there are no actual in vivo data on the rate at 
which unconjugated BPA is converted to BPA-
glucuronide in humans, only estimates. BPA 
is lipophilic with a log octanol–water partition 
coefficient (log Kow) between 2.2 and 3.82, and 
it may partition to lipid-rich tissues, a sugges-
tion supported by population-based half-lives 
for BPA calculated by Stahlhut et al. (2009) 
to be significantly longer than previous predic-
tions of 6 hr. Given the correlations with BMI 
and waist circumference seen here, a true esti-
mation of exposure rates remains a priority.
There are limitations to this study that 
should be borne in mind when interpreting 
the results. First, replication is required in 
an independent study population to exclude 
chance as an explanation, although the small 
p-value in fully adjusted models and the broad 
consistency with previous work suggest this is 
unlikely. Second, the analysis is based on a 
single day of BPA excretion, which is clearly 
not a perfect measure of longer term exposure 
given that human health effects are most likely 
associated with long-term low-dose exposure. 
However, using the 24-hr urine specimens 
is likely to be more accurate than previously 
published work, which has been based on spot 
urine samples with post hoc adjustment to try 
to correct for concentration effects. Spot urine 
samples themselves have been shown to be 
moderately sensitivity for predicting an indi-
vidual’s tertile categorization (Mahalingaiah 
et al. 2008). Misclassification due to this 
single-day snapshot of excretion will have 
resulted in a smaller (diluted) estimate of the 
strength of association between BPA and total 
testosterone concentrations: the true associa-
tions are likely to be much stronger.
Third, the cross-sectional nature of the 
association reported here needs to be treated 
with caution. It is also theoretically possible, 
for example, that those with higher testoster-
one concentrations alter their diet in such a 
way as to increase BPA exposure, or, as noted 
above, that higher testosterone concentra-
tions are themselves responsible for altering 
metabolism of BPA. It is unclear, however, 
why altered metabolism would alter our 
measure of 24-hr excretion systematically, 
because all BPA is thought to be excreted in 
the urine in humans sooner or later. We pre-
viously reported positive associations between 
urinary BPA and prevalence of cardio vascular 
disease (Lang et al. 2008; Melzer et al. 2010). 
The relationship between circulating testos-
terone and cardiovascular risk remains to be 
comprehensively established, although an 
increased risk of cardiovascular adverse events 
was recently reportedly in a trial of testoster-
one supplementation in older men (Basaria 
et al. 2010).
Future work needs to replicate the asso-
ciation found and to clarify the mechanisms 
involved. Showing that raised BPA levels pre-
cede the increase in testosterone concentra-
tions would establish the temporal sequence 
of changes and exclude reverse causation. 
However, a concurrent change in testoster-
one levels with BPA exposure would remain 
biologically important. A large-scale exposure 
trial may be necessary to clarify the association 
we identified, although the logistics and ethics 
of such a trial would require careful thought.
Conclusions
Mean daily exposure to BPA among an Italian 
adult population sample is in line with previous 
estimates from the United States, with wide 
variations around the mean. We found an asso-
ciation between higher daily excretion of BPA 
and total testosterone concentrations among 
men. The mechanisms involved in this possible 
endocrine disruption need clarification.
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Bisphenol A (BPA) is a synthetic compound 
that is suspected to act as an endocrine dis-
ruptor (i.e., a compound capable of causing 
dysfunction to hormonally regulated body sys-
tems) (Talsness et al. 2009). It was originally 
synthesized as a synthetic estrogen (Dodds 
and Lawson 1936). It is used extensively as 
a monomer in polycarbonate plastics and in 
the epoxy resins that are used to line food 
and beverage containers and is one of the 
world’s highest-production-volume chemi-
cals (Ritter 2011). Ubiquitous exposure to 
BPA is believed to occur mainly through the 
diet, with additional contributions from den-
tal sealants, dermal exposure, and inhalation 
of household dusts. BPA metabolites have 
been reported in the urine of > 90% of people 
in representative population samples in the 
United States and Europe (Calafat et al. 2008; 
Galloway et al. 2010).
Whether BPA can cause human health 
effects is a matter of some debate. There 
has been concern about the potential for a 
relation ship between BPA and negative health 
effects, including increases in abnormal penile/
urethra develop ment in males, early sexual 
maturation in females, an increase in neuro-
behavioral problems such as attention deficit–
hyperactivity disorder (ADHD) and autism, 
an increase in childhood and adult obesity and 
type 2 diabetes, and an increase in hormon-
ally mediated cancers, such as prostate and 
breast cancers (reviewed by Hengstler et al. 
2011; vom Saal et al. 2007). Cross-sectional 
epidemiological studies have shown higher 
BPA exposure to be associated with adverse 
health effects in the general adult population. 
In a study of 1,455 respondents in the 2003–
2004 U.S. population-representative National 
Health and Nutrition Examination Survey 
(NHANES), higher urinary BPA concentra-
tions were associated with cardio vascular dis-
ease diagnoses and with diagnosed diabetes 
but not with other common diseases, suggest-
ing specificity of the reported findings (Lang 
et al. 2008). In a further study of data from 
NHANES 2005/2006, higher BPA concen-
trations were again associated with coronary 
heart disease, providing independent repli-
cation of the findings (Melzer et al. 2010). 
Higher exposure to BPA has also been associ-
ated with reproductive and develop mental 
abnormalities. In a study of 249 mothers and 
their children, prenatal urinary BPA concen-
trations in mothers were prospectively associ-
ated with externalizing behavior scores among 
their children when measured at 2 years of 
age (Braun et al. 2009). A positive association 
was also shown between BPA exposure and 
recurrent miscarriage in a prospective study of 
67 women (Sugiura-Ogasawara et al. 2005). 
The mechanisms under lying these potential 
health effects remain to be determined.
Most studies of the health effects of 
BPA have focused on its estrogenic activity 
because it is widely documented to function 
as an agonist of certain estrogen receptors 
(ERs) (Lee et al. 2003) and as an androgen 
antagonist and to suppress aromatase activity 
(Bonefeld-Jørgensen et al. 2007). Additional 
receptor-mediated biological activities, includ-
ing binding to the orphan estrogen-related 
receptor ERRγ (Okada et al. 2008), thyroid 
hormone disruption (Moriyama et al. 2002), 
altered pancreatic β-cell function (Ropero 
et al. 2008), and obesity-promoting effects 
(Newbold et al. 2008), have been reported 
in different model systems. Many of these 
effects are already detectable in the nano-
molar range, prompting calls for a revision 
to the current tolerable daily intake (TDI) of 
50 μg/kg/day. However, until now, there has 
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Bisphenol A Exposure Is Associated with in Vivo Estrogenic Gene Expression 
in Adults
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Background: Bisphenol A (BPA) is a synthetic estrogen commonly used in polycarbonate plastic and 
resin-lined food and beverage containers. Exposure of animal and cell models to doses of BPA below 
the recommended tolerable daily intake (TDI) of 50 μg/kg/day have been shown to alter specific 
estrogen-responsive gene expression, but this has not previously been shown in humans.
oBjective: We investigated associations between BPA exposure and in vivo estrogenic gene expres-
sion in humans.
Methods: We studied 96 adult men from the InCHIANTI population study and examined in vivo 
expression of six estrogen receptor, estrogen-related receptor, and androgen receptor genes in 
peripheral blood leukocytes.
results: The geometric mean urinary BPA concentration was 3.65 ng/mL [95% confidence inter-
val (CI): 3.13, 4.28], giving an estimated mean excretion of 5.84 μg/day (95% CI: 5.00, 6.85), 
significantly below the current TDI. In age-adjusted models, there were positive associations 
between higher BPA concentrations and higher ESR2 [estrogen receptor 2 (ER beta)] expression 
(unstandardized linear regression coefficient = 0.1804; 95% CI: 0.0388, 0.3221; p = 0.013) and 
ESRRA (estrogen related receptor alpha) expression (coefficient = 0.1718; 95% CI: 0.0213, 0.3223; 
p = 0.026): These associations were little changed after adjusting for potential confounders, includ-
ing obesity, serum lipid concentrations, and white cell sub type percentages. Upper-tertile BPA 
excretors (urinary BPA > 4.6 ng/mL) had 65% higher mean ESR2 expression than did lower-tertile 
BPA excretors (0–2.4 ng/mL).
conclusions: Because activation of nuclear-receptor–mediated pathways by BPA is consistently 
found in laboratory studies, such activation in humans provides evidence that BPA is likely to 
function as a xenoestrogen in this sample of adults.
key words: bisphenol A, endocrine disruption, estrogen receptor-β, estrogen-related receptor-α, 
human biomonitoring, InCHIANTI, toxicogenomics. Environ Health Perspect 119:1788–1793 
(2011). http://dx.doi.org/10.1289/ehp.1103809 [Online 10 August 2011]
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been no evidence that BPA at these low levels 
exerts significant biological effects in humans, 
and hence the TDI has remained unaltered 
(European Food Safety Authority 2010).
A recent cross-sectional examination 
of circulating sex hormone concentrations 
in 307 men showed higher BPA levels to be 
associated with changes in total testosterone 
concentrations [β = 0.046; 95% confidence 
interval (CI): 0.015, 0.076; p = 0.004 in fully 
adjusted models] (Galloway et al. 2010). There 
was no significant trend in 17β-estradiol lev-
els with higher BPA in men, although an 
earlier study of 167 men recruited through 
an infertility clinic used multiple adjusted 
regression models to show BPA concentra-
tions in urine to be inversely associated with 
the estradiol:testosterone ratio (Meeker et al. 
2010). Plausible explanations for these endo-
crine changes include altered expression of 
hormone-responsive genes. To date there is no 
in vivo evidence for changes in sex-hormone–
responsive gene expression associated with 
human exposure to BPA.
Here, we aimed to test the hypothesis that 
exposure to BPA would be associated with 
changes in the in vivo expression of estrogen- 
and androgen-responsive genes. To do this, we 
conducted a cross-sectional study to character-
ize six candidate estrogen- or androgen-related 
transcripts for differential in vivo expression in 
response to BPA exposure. The study popula-
tion was selected from the InCHIANTI study, 
a large European population representative 
sample based in Chianti, Italy.
Materials and Methods
Study population. The InCHIANTI study, a 
prospective population-based study of Italian 
adults (InCHIANTI 2011), was designed 
to identify risk factors for mid- and late-life 
morbidity in urban and rural populations 
and has been described extensively elsewhere 
(Ferrucci et al. 2000). InCHIANTI is per-
formed in two sites: Greve in Chianti (11,709 
inhabitants) and Bagno a Ripoli (Village of 
Antella, 4,704 inhabitants). The final study 
population included 1,453 persons (age range 
20–102 years) stratified across age ranges using 
a multi stage sampling process, with a response 
rate of 91.6% from the baseline interview. 
Subjects and specimens selected for the pres-
ent study were those with the most adequate 
RNA and urine specimens in the 2008/2009 
follow-up, and ≤ 76 years of age, in line with 
previous work. Women were excluded from 
this analysis because of cyclic hormonal varia-
tions in pre menopausal subjects. The Instituto 
Nazionale Riposo e Cura Anziani Institutional 
Review Board (Florence, Italy) provided ethi-
cal approval. All participants gave informed 
(or surrogate) consent.
Sample collection. Participants who con-
sented to give a blood sample were also asked 
to provide a spot morning urine sample, which 
was stored at –20°C until further analy sis. First 
thing in the morning on the day of the study 
visit, after participants had been sedentary for 
15 min, fasting blood samples were collected 
for routine blood examination, and periph-
eral blood specimens preserving in vivo RNA 
expression were collected using PAXgene tech-
nology (Debey-Pascher et al. 2009).
Analysis of urinary BPA concentrations. 
Samples were analyzed at the Brixham 
Environmental Laboratory Division of 
Analytical Chemistry (a division of AstraZeneca 
PLC; Brixham, UK) in compliance with Good 
Laboratory Practice, EU Directive 88/32/
EEC (United Kingdom 2004). BPA ingested 
in humans is almost completely metabolized 
and rapidly excreted, so urine is considered 
the most appropriate matrix for assessment of 
exposure (Calafat et al. 2005). As part of our 
extensive Good Laboratory Practice–compliant 
quality control, we included reagent blanks 
and confirmed that samples stored for up to 
10 years contained predominantly metabo lized 
compound, confirming minimal leaching of 
BPA from collection or storage vessels during 
this time. BPA concentrations were meas ured in 
spot urine samples by liquid chromatography–
mass spectrometry. Total (free and conjugated) 
urinary concentrations of BPA were obtained 
using online, solid-phase extraction coupled 
with high-performance liquid chromatography–
isotope dilution tandem mass spectrometry 
with peak focusing, as described previously 
(Galloway et al. 2010). Calibration was linear 
from 0.50 to 100 μg/L (R2 > 0.996), limit of 
detection was < 0.50 ng/mL BPA, the limit 
of quantification was 0.50 ng/mL BPA, and 
the lowest calibration standard gave a signal 
height:noise ratio > 10 (relative standard 
deviations < 20%, all other standards < 15%).
Gene expression by real-time reverse-
 transcriptase polymerase chain reaction 
(RT-PCR). Blood leukocytes were used for 
transcript analysis because they are convenient 
and available and because they provide suf-
ficient power in large cohorts where access 
to other tissues is lacking. Because BPA 
is metabolized in the intestines and liver to 
form predominantly BPA-monoglucuronide, 
which is passed through the bloodstream to 
the kidney, exposure of leukocytes to BPA 
and/or its metabolites is inevitable. To test 
the hypothesis that exposure to BPA would 
be associated with changes in the expression 
of estrogen- and androgen-responsive genes, 
we correlated BPA levels as a continuous trait 
with the expression of ER, androgen receptor 
(AR), and estrogen-related receptor (ERR) 
genes by quantitative real-time PCR in a sub-
set of 100 male subjects. These genes were 
chosen because the nuclear hormone receptors 
they encode are transcription factors that con-
trol essential develop mental and physiological 
pathways and because activation of these 
nuclear-receptor–mediated pathways by BPA 
is consistently found in laboratory studies.
Total RNA (100 ng) was reversed tran-
scribed in 20 μL reactions using the Superscript 
III VILO kit (Invitrogen, Paisley, UK), accord-
ing to the manufacturer’s instructions.
The expression levels of ESR1 (estrogen 
receptor 1; ERα), ESR2 [estrogen recep-
tor 2 (ER beta); ERβ], ESRRA (estrogen 
related receptor alpha; ERRα), ESRRB (estro-
gen related receptor beta; ERRβ), ESRRG 
(estrogen related receptor gamma), and AR 
(androgen receptor) genes were then assessed 
relative to the endogenous control genes GUSB 
(glucuronidase, beta) and ACTB (actin, beta; 
β-actin) on the TaqMan Low Density Array 
(TLDA) platform (Applied Biosystems, Foster 
City, CA, USA). Probes were inventoried 
with Applied Biosystems assays Hs01046812_
m1, Hs01100358_m1, Hs01584024_m1, 
Hs00155006_m1,  Hs00907244_m1, 
Hs99999908_m1, and Hs03023943_g1 for 
ESR1, ESR2, ESRRB, ESRRG, AR, GUSB, 
and ACTB genes, respectively. These probes 
were chosen because they are documented to 
pick up all isoforms and splice variants for the 
genes of interest.
The expression of the ESRRA gene was 
assessed by the use of a custom assay (probe 
and primer sequences available on request). 
Reaction mixes included 50 μL 2× TaqMan 
universal master mix (no AMPerase; Applied 
Biosystems), 40 μL distilled H2O, and 10 μL 
cDNA template per TLDA loading port. 
PCR amplifications were performed on the 
ABI 7900HT platform (Applied Biosystems). 
Cycling conditions were 50°C for 2 min, 
94.5°C for 10 min followed by 40 cycles 
of 97°C for 30 sec and 57.9°C for 1 min. 
The expression of each gene was measured 
in triplicate for each sample. Gene expres-
sion relative changes were quantified using 
the 2–ΔΔCt method (Livak and Schmittgen 
2001) relative to the geometric mean of the 
endogenous controls listed above using the 
StatMiner relative quantification software for 
high-throughput integrated analysis of TLDA 
data (Integromics, Grenada, Spain).
Statistical analysis. We assessed the asso-
ciation of candidate gene expression levels 
with urinary BPA concentration by multi-
variable linear regression. Data were adjusted 
for potential confounding factors that could 
influence BPA exposure or candidate gene 
expression: age (reported in years at the last 
birthday and used as a continuous variable); 
body mass index (BMI) calculated as weight 
in kilograms divided by height in meters 
squared; waist circumference (as a continu-
ous trait); highest level of education attained 
(in four categories: none/elementary, second-
ary, high school, and university/professional); 
low-density lipoprotein (LDL) cholesterol 
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(milligrams per deciliter); triglycerides (milli-
grams per deciliter); and study site [individu-
als were drawn from a rural village (Greve) 
and an urban population (Bagno a Ripoli)]. 
Models were also adjusted for the percentage 
of neutrophils (neutrophil%), lymphocytes 
(lymphocyte%), monocytes (monocyte%), 
and eosinophils (eosinophil%) [the percent-
age of basophils (basophil%) was not added 
because the cell subtype percentages would 
have equaled 100%].
The expression value of each of the target 
genes was not normally distributed, and we 
used natural log transformation when gene 
expression was considered as a dependent 
variable. In all analyses, an upper age cut-
off was 76 years to minimize the problem of 
comorbidity. Data analysis was performed 
using STATA (version 10 SE; StataCorp LP, 
College Station, TX, USA); p < 0.05 was con-
sidered significant.
We used generalized additive mod-
els with penalized cubic regression splines 
(Wood 2006) to explore the functional form 
of the relationship between candidate gene 
expression levels and urinary BPA concentra-
tion. Linearity of the relationship between 
log-transformed expression level and log-
transformed BPA concentration was assessed 
by visual inspection of the estimated spline 
functions and by examining the estimated 
degrees of freedom (edf) for the smoothed 
BPA term. Values of the edf close to 1 were 
taken as evidence of linearity. Adjustment 
was made for the same potential confounding 
factors that were included in the multi variable 
linear regression models. The prediction error 
criterion for smoothness selection was gen-
eralized cross-validation. Robustness of the 
smoothness selection was assessed by making 
comparisons with the use of maximum likeli-
hood estimation. The spline models were fit-
ted using R statistical software using the mgcv 
package for generalized additive modeling 
(version 2.12.1; R Project for Statistical 
Computing 2010). 
Results
The sample (n = 96; Table 1) had a mean age 
of 58.3 years (range, 32–76 years) and a mean 
(± SD) BMI of 27.8 ± 4.1 kg/m2. The geo-
metric mean urinary BPA concentration was 
3.65 ng/mL (95% CI: 3.13, 4.28) ranging 
from 0.73 to 56.94 ng/mL (limit of detection 
< 0.5 ng/mL). The distribution was skewed, 
with a 10th percentile of 1.3 ng/mL and a 
90th percentile of 10.4 ng/mL. The estimated 
mean excretion was 5.84 μg/day (95% CI: 
5.00, 6.85).
The expression of transcripts associated with 
sex-hormone–related signaling was quantified 
by real-time RT-PCR (Table 2). Expression 
of ESRRG was not detected in our samples. 
There was only one significant correlation of 
expression intensities between probes: between 
ESR1 and ESR2 (pairwise correlation = 0.24; 
p = 0.02). We obtained valid expression inten-
sity measures for 96 men for the ESR2 gene 
and 83 men for the ESRRA gene (Table 2). 
BPA concentrations in the 96 respondents with 
successful ESR1 expression measures were no 
different from the remaining 55 respondents 
< 76 years of age (age-adjusted regression with 
log-transformed BPA concentration: unstan-
dardized linear regression coefficient = 0.012; 
95% CI: –0.114, 0.138; p = 0.848) for which 
meas ured BPA values were available. 
Using urinary BPA concentrations as 
a continuous variable, we tested linear asso-
ciations between BPA and gene expression. 
In age-adjusted regression models of log-
transformed BPA concentrations against 
log-transformed expression levels (Table 3), 
we observed positive associations with ESR2 
(ERβ; coefficient = 0.1804; 95% CI: 0.0388, 
0.3221; p = 0.013) and ESRRA (ERRα, coef-
ficient = 0.1718, 95% CI: 0.0213, 0.3223, 
p = 0.026) but not with ESR1(ERα), 
ESRRB(ERRβ), or AR. 
In models additionally adjusted for previ-
ously suggested confounders (Sharpe 2010) 
(BMI, LDL cholesterol and triglyceride 
concentrations, study site, and educational 
attainment—a proxy for social position) and 
white cell subtype percentages, the results were 
little changed: for ESR2, coefficient = 0.1387; 
95% CI: 0.001, 0.2764; p = 0.048; for ESRRA 
coefficient = 0.1886; 95% CI: 0.0324, 0.3448; 
p = 0.019) (Table 4). 
When using an alternative exposure metric 
of dividing BPA concentrations into tertiles 
in the fully adjusted models (Figure 1), par-
ticipants in the lowest BPA exposure tertile 
had a geometric mean expression of ESR2 
of 0.80 IU (95% CI: 0.65, 0.99), rising to 
1.32 IU (95% CI: 1.08, 1.60) in the highest 
tertile, a 65% increase in mean expression. 
For ESRRA, the same measures were 0.66 IU 
(95% CI: 0.49, 0.89) and 0.91 IU (95% CI: 
0.78, 1.06), a 38% increase in mean expres-
sion of the gene.
Figure 2A shows a spline plot for the 
change in natural log of ESR2 expression as 
a function of log-transformed urinary BPA 
concentration. This suggests that the posi tive 
association between ESR2 and BPA concen-
tration is curvilinear (edf = 1.45; p-value for 
smoothed term = 0.027), with evidence of 
a diminishing effect as BPA concentration 
increases. A similar spline plot for ESRRA 
expression is shown in Figure 2B. This sug-
gests that the relationship with BPA con-
centration is linear for this ERR (edf = 1.00; 
p‑value for smoothed term = 0.017).
Table 1. Characteristics of the sample (n = 96).
Characteristic Mean ± SD (range)a
Age (years) 58.3 ± 15.2 (32–76)
Site (%)
Greve 38.4
Bagno a Ripoli 61.5
Education (%)
None/elementary 22.9
Secondary school 26.0
High school 35.4
Professional/university 16.6
BMI (kg/m2) 27.8 ± 4.1 (18.38–42.99)
LDL cholesterol (mg/dL) 125.4 ± 29.8 (60–220)
Triglycerides (mg/dL) 137.3 ± 75.3 (45–469)
Neutrophils% 55.2 ± 9.7 (26.2–79.1)
Lymphocytes% 32.8 ± 9.2 (9.1–59.9)
Monocytes% 8.4 ± 2 (4.3–21.3)
Eosinophils% 3 ± 1.7 (0.1–10.3)
Basophils% 0.5 ± 0.2 (0.1–1.4)
aValues shown are mean ± SD (range) except where 
indicated. 
Table 2. Expression characteristics of the tested estrogen and androgen target genes.
Target gene Assay IDa Accession numberb n Mean ± SD (range)
ESR1 Hs01046812_m1 NM_000125 96 1.21 ± 0.535 (0.365–3.165)
ESR2 Hs01100358_m1 NM_001040275 96 1.294 ± 0.899 (0.167–5.585)
ESRRA Hs01067166_g1 NM_004451 83 0.882 ± 0.33 (0.105–1.991)
ESRRB Hs01584024_m1 NM_004452 96 2.974 ± 2.434 (0.000–10.363)
ESRRG Hs00155006_m1 NM_206595 Not expressed
AR Hs00907244_m1 NM_000044.2 96 1.232 ± 0.673 (0.188–3.295)
aTaqMan Gene Expression assay identification number. bAccession numbers from the National Center for Biotechnology 
Information (2011). 
Table 3. Estimates for the associations between natural log of urinary BPA concentrations and gene 
expression intensity (log transformed), in age-adjusted and fully adjusteda regression models.
Age-adjusted model Fully adjusted model
Gene Coefficient (95% CI) p-Value Std β Coefficient (95% CI) p-Value Std β
ESR1 –0.0657 (–0.1815, 0.0500) 0.262 –0.117 –0.1071 (–0.2205, 0.0063) 0.064 –0.1909
ESR2 0.1804 (0.0388, 0.3221) 0.013 0.231 0.1387 (0.001, 0.2764) 0.048 0.1775
ESRRA 0.1718 (0.0213, 0.3223) 0.026 0.250 0.1886 (0.0324, 0.3448) 0.019 0.2699
ESRRB –0.2816 (–1.3969, 0.8337) 0.617 –0.054 –0.4857 (–1.6669, 0.6955) 0.416 –0.0925
ESRRG ND ND
AR 0.0115 (–0.1404, 0.1634) 0.881 0.016 0.0925 (–0.0646, 0.2495) 0.245 0.1285
Abbreviations: ND, not detected; Std, standardized.
aFull adjustment included age, BMI, study site, educational attainment, and LDL cholesterol and tri glyceride concentra-
tions, plus percentages of neutrophils, lymphocytes, monocytes, and eosinophils. 
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Discussion
In this study, we aimed to assess whether 
increased urinary BPA concentrations were 
associated with changes in gene expression 
in vivo in the general adult population. We 
made use of a large-scale and high-quality pop-
ulation-representative data set for which speci-
mens preserving in vivo RNA expression were 
available. We were able to measure in vivo 
expression of five ER, ERR, and AR genes in 
peripheral blood leuko cytes in 96 adult men. 
Using urinary BPA excretion as a marker of 
exposure, we found that those with higher 
BPA exposures had higher expression of two 
estrogen-responsive genes, ESR2 (ERβ) and 
ESRRA (ERRα).
These findings are important because they 
suggest that BPA is bioactive in the human 
body and that associations with hormone sig-
naling and related disorders are biologically 
plausible. ERβ, which showed the strongest 
association with BPA exposure, is one of two 
ER subtypes that, along with ERα, medi-
ates the physiological actions of estrogens 
(Swedenborg et al. 2009). ERβ and ERα have 
distinct tissue distribution, ligand specificities, 
and functions; ERα is predominant in the reg-
ulation of female reproduction, whereas ERβ 
is important in maintaining the structure and 
function of non classic target tissues, including 
prostate, colon, and cardio vascular and central 
nervous systems (Imamov et al. 2005). BPA 
displays estrogenic agonist activities against 
both ERα and ERβ subtypes in vitro, with 
relatively high ERβ selectivity (Matthews 
et al. 2001), consistent with our findings. The 
modulation by BPA of ER gene expression 
has previously been shown in animal mod-
els, at environmentally relevant concentra-
tions. For example, exposure of rat prostate 
mesenchyme cells to 1 nM BPA led to altered 
ER gene expression, accompanied by modest 
stimulation of cell growth, with a threshold 
of induction around 30-fold less potent than 
17β-estradiol (Richter et al. 2007).
ERRα belongs to the NR3B orphan 
nuclear receptor subgroup, which consists of 
ERRα, ERRβ, and ERRγ (Hong et al. 1999). 
All three ERRs show close sequence identity 
to the ERα DNA binding domain and also 
feature a conserved C-terminal domain with 
a putative ligand binding domain and inter-
action surfaces for coregu la tors, and a less con-
served N-terminal domain (Giguère 2002). 
Despite this close structural homology to the 
ERs, estradiol does not bind to ERRα, and 
X-ray crystallography of the putative ligand-
binding domain pocket of ERRα shows it to 
be almost completely occupied by side chains. 
This supports the suggestion that ERRα shows 
ligand-independent transcriptional activa-
tion and is largely dependent on its functional 
interaction with coregulators, including peroxi-
some proliferator-activated receptor-γ (PPARγ) 
coactivator 1α (PGC-1A) and PGC-1B for 
optimal gene regulation (Ranhotra 2010). In 
adults, ERRα is constitutively expressed in tis-
sues that preferentially use fatty acids as energy 
sources, including adipose tissue, heart, and 
skeletal muscle, where it plays a significant role 
in regulating energy homeo stasis and adaptive 
oxidative capacity (Dufour et al. 2007). These 
functions are thought to involve close coopera-
tion with PGC-1A and ERRγ (Villena and 
Kralli 2008). Crucially, BPA binds to ERRγ 
with high affinity (Okada et al. 2008), and 
ERβ has been identified as an important regu-
lator of PPARγ (Foryst-Ludwig et al. 2008).
Given the structural homology between 
ERs and ERRs, particularly in the DNA-
binding domain, involvement of ERRs in 
estrogenic signaling pathways is not unex-
pected (Giguère 2002). ERRα has been 
proposed as a regulator of aromatase activ-
ity (Yang et al. 1998), and in turn, estradiol 
induces up-regulation of ERRα in some tis-
sues (Shigeta et al. 1997). ERRα stimulation 
of androgen-responsive element–containing 
promoters illustrates the potential for cross-
talk with signaling driven by other steroid 
hormones (Teyssier et al. 2008).
The functional relevance of changes in 
ERβ and ERRα expression in blood leuko-
cytes has not been determined. Because estro-
gens and androgens can exert differential 
effects in function depending on the cell type 
and its stage of development, the consequences 
Table 4. Multiple regression model estimates for the associations between explanatory variables and natural logs of ESR2 and ESRRA gene expression.
ESR2 ESRRA
Variable Coefficient (95% CI) p-Value Std β Coefficient (95% CI) p-Value Std β
BPA concentration (log transformed) 0.1387 (0.001, 0.2764) 0.048 0.1775 0.1886 (0.0324, 0.3448) 0.019 0.2699
Age –0.0169 (–0.0261, –0.0078) < 0.001 –0.4256 0.0018 (–0.0086, 0.0122) 0.733 0.0470
BMI 0.0206 (–0.0057, 0.0468) 0.122 0.1399 –0.0023 (–0.0312, 0.0265) 0.873 –0.0194
Study site 0.2016 (–0.0098, 0.413) 0.061 0.1629 –0.218 (–0.4489, 0.0129) 0.064 –0.2087
Educational attainment
None/elementary 1 1
Secondary 0.1146 (–0.2084, 0.4375) 0.482 0.0834 –0.4742 (–0.8521, –0.0962) 0.015 –0.4176
High school –0.0347 (–0.3704, 0.3011) 0.838 –0.0275 –0.099 (–0.4865, 0.2885) 0.612 –0.0929
Professional/university 0.0899 (–0.2604, 0.4403) 0.611 0.0542 –0.0379 (–0.4521, 0.3764) 0.856 –0.0268
LDL cholesterol (mg/dL) –0.0024 (–0.006, 0.0012) 0.195 –0.117 0.0016 (–0.0022, 0.0055) 0.407 0.094
Triglycerides (mg/dL) 0.0012 (–0.0002, 0.0025) 0.095 0.1444 –0.0009 (–0.0023, 0.0006) 0.255 –0.1339
Neutrophil% –0.3194 (–0.8618, 0.2229) 0.245 –5.1245 0.3622 (–0.2803, 1.0047) 0.265 6.5463
Lymphocyte% –0.302 (–0.845, 0.2411) 0.272 –4.606 0.3611 (–0.2828, 1.0049) 0.267 6.1452
Monocyte% –0.2982 (–0.8349, 0.2385) 0.272 –1.0051 0.3678 (–0.265, 1.0007) 0.250 1.5245
Eosinophil% –0.3075 (–0.8726, 0.2575) 0.282 –0.8726 0.3624 (–0.2947, 1.0196) 0.275 1.2623
Constant 31.078 (–23.088, 85.244) 0.257 –36.1216 0.264 0
Std, standardized. “Constant” refers to the intercept term in the multiple regression model; it gives the expected log-transformed gene expression level when all other variables in the 
model are set to zero.
Figure 1. Box plot of ESR2 and ESRRA probe intensity by urinary BPA concentration. Boxes extend from 
the 25th to the 75th percentile, horizontal bars represent the median, whiskers indicate the 10th and 90th 
percentiles, and outliers are represented as circles. 
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of BPA exposure on a wider range of adult 
reproductive and somatic tissues merits further 
attention (Goodman et al. 2008). However, 
up to 50% of expression changes in leukocytes 
for highly heritable cis-acting traits are also 
mirrored in other tissues such as adipose tissue, 
making them viable surrogates for exposure of 
other tissues (Emilsson et al. 2008). Human 
adipocytes express both ERβ and ERRα 
(Hugo et al. 2008), and adipocyte explants 
respond to both BPA and 17β-estradiol expo-
sure in the nano molar range by accumulating 
lipid. Taken together, these results are strongly 
suggestive of specific and targeted bioactivity 
of BPA in vivo, even if the clinical relevance, if 
any, of these findings is not yet clear.
One limitation of this analysis is its 
cross-sectional nature. Virtually all individu-
als are exposed, and because clinical trials to 
administer BPA in human subjects are ethi-
cally unacceptable, collecting longitudinal data 
demonstrating that BPA exposure induces 
gene expression changes in vivo is not cur-
rently achievable.
It is feasible that the increases in gene 
expression that we measured are associated 
with confounding variables that have not been 
accounted for in our models. For example, 
there are time-dependent changes in ERβ 
expression, both on a long-term scale, such 
as in fetal and post natal development, and in 
short-term oscillations during the circadian 
cycle (Swedenborg et al. 2009). Although it is 
not possible to completely account for circa-
dian cycles, all samples were taken at a similar 
time of day, and we restricted our analysis to 
men rather than women to minimize the influ-
ence of cyclic variation in endogenous hor-
mones. Confounding variables that could affect 
BPA exposure include higher food intakes or 
obesity, which could be accompanied by inci-
dentally higher intakes of BPA (Sharpe 2010). 
Our secondary analyses included adjustment 
for BMI and LDL cholesterol and triglyceride 
concentrations, and these made minimal dif-
ference to the overall results, arguing against 
obesity as an explanation for our findings. We 
found no associations between serum lipids and 
expression intensities of our candidate genes.
Another consideration is that we quan-
tified BPA metabolites in urine, while gene 
expression was measured in blood leuko cytes. 
BPA ingested in humans is rapidly excreted, so 
urine is considered the most viable biomoni-
toring approach for BPA, as detailed by 
Calafat et al. (2005). Single spot samples are 
limited measures of longer-term exposure, but 
a in study of temporal variability in urinary 
BPA metabolites, Mahalingaiah et al. (2008) 
found that a single spot sample had moder-
ate sensitivity for predicting an individual’s 
tertiary categorization. Nepomnaschy et al. 
(2009) meas ured stability of BPA over 2-week 
intervals in first voided urine samples from 
60 women and found a Spearman correlation 
of 0.5, indicating that within-individual BPA 
exposures were generally stable over periods 
of weeks. They also showed that the stability 
of BPA in long-term frozen samples is good. 
The stability of free BPA in urine was also 
confirmed by Ye et al. (2011).
The mean BPA concentration in our study 
was 3.65 ng/mL, and assuming an average 
24-hr urine volume of 1,600 mL in adult men 
(Galloway et al. 2010), a 100% excretion rate, 
and a total blood volume of 6 L, the estimated 
concentration of BPA in the blood was in 
the low nanogram per milliliter range. The 
in vitro IC50 (half-maximal inhibitory con-
centration) for human ERβ receptor binding 
of BPA is in the micro molar range (Matthews 
et al. 2001), which would imply low ER occu-
pancy rates. Given that functional effects of 
BPA on nuclear receptor expression have also 
been reported in both animal and human cells 
at this concentration, in vitro measurement 
may not be indicative of the in vivo situation 
where differential binding to carrier proteins 
and receptors may occur. There are no in vivo 
data on the rate at which BPA is converted 
to BPA-monoglucuronide and excreted from 
the body, only estimates, and because BPA 
is lipophilic with a log octanol–water parti-
tion coefficient (Kow) of 2.2–3.82, distribu-
tion to lipid-rich tissues is a possibility. This 
suggestion is supported by population-based 
half-lives for BPA calculated by Stahlhut et al. 
(2009) to be significantly longer than previous 
predictions of 6 hr.
The major metabolite of BPA, BPA-
monoglucuronide, has no estrogenic activity, 
but oxidative cleavage of BPA to form the 
estrogenically active metabolite 4-methyl-2,4-
bis(4-hydroxyphenyl)pent-1-ene (MBP) has 
been observed in rat liver. Okuda et al. (2010) 
reported that MBP was 500-fold more potent 
than BPA itself in inducing dose- dependent 
changes in expression of ERα and ERβ 
mRNA. The signifi cance of this metabolite in 
humans is not yet known. However, a com-
parison of the phase 1 metabolism of BPA in 
rat and human liver micro somes identified the 
oxidation product BPA-catechol to be a minor 
(~ 10%) metabolite in both species. BPA-
catechol is considered to be a weak estrogen 
(Nakagawa and Suzuki 2001), suggesting that 
further investigation of the phase 1 metabo-
lism of BPA in humans and the estrogenic 
potency of all metabolites is merited (Ye et al. 
2011).
Conclusion
We provide the first report of associations 
between BPA exposure and in vivo estrogenic 
gene expression in humans. We examined 
in vivo expression of six ER, ERR, and AR 
genes in peripheral blood leuko cytes from 
96 adult men from the InCHIANTI popula-
tion study. We observed positive associations 
between higher urinary BPA concentrations 
and higher expression of two estrogen-respon-
sive genes, encoding ERβ and ERRα. The asso-
ciations remained statistically significant when 
adjusted for potential confounders, includ-
ing obesity and serum lipid concentrations. 
The individuals in the upper tertile of BPA 
exposure showed 65% higher mean expression 
of the ESR2 (ERβ) gene in peripheral blood 
Figure 2. Cubic regression spline models illustrating the functional form of the relationship between log-transformed urinary BPA concentration and ESR2 (A) and 
ESSRA (B) gene expression. 
0
0.5
0
–0.5
0.6
0.4
0.2
0
–0.2
–0.4
–0.6
1 2 3 4
Ch
an
ge
 in
 n
at
ur
al
 lo
g 
of
 E
SR
2
–0.5 0 0.5 1.0 1.5 2.0 2.5 3.0
Log-transformed BPA concentration (ng/mL) Log-transformed BPA concentration (ng/mL)
Ch
an
ge
 in
 n
at
ur
al
 lo
g 
of
 E
SR
RA
Bisphenol A and gene expression in vivo
Environmental Health Perspectives • volume 119 | number 12 | December 2011 1793
leukocytes than did those in the lower tertile. 
Although the clinical significance of these 
results is not yet known, such activation in 
humans provides evidence that BPA is likely to 
function as a xeno estrogen in this population-
representative sample of adults. This prompts 
a need for replication and scien tific follow-up, 
for example, in examining the relationship 
between gene expression changes and protein 
expression and effects of BPA exposure in a 
wider range of estrogen-regulated target tissues.
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 Abstract 
Bisphenol A (BPA) is a widely used plastics constituent that has been associated with 
diabetes, cardiovascular disease and altered metabolic regulation. Evidence for how BPA 
exerts significant biological effects at chronic low levels of exposure has remained elusive. In 
adult men, exposure to BPA has been associated with higher expression of two nuclear 
receptors, estrogen-receptor beta (ERβ) and estrogen-related-receptor-alpha (ERRα), in 
peripheral white blood cells in vivo. Here we explore the expression of ESR2 (ERβ) and 
ESRRA (ERRα) in human leukaemic T cell lymphoblasts (Jurkat cells) exposed to BPA and a 
BPA putative metabolite in vitro. We show that exposure to BPA led to enhanced expression 
of ESRRA within 6 hours of exposure (mean±SEM: 1.43±0.08 fold increase compared to the 
control, p<0.05). After 72h, expression of ESRRA remained significantly enhanced at 
concentrations of BPA ≥ 1nano molar (nM). Oxidative metabolism of BPA by rat liver S9 
fractions yields the potent estrogenic metabolite 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-
ene (MBP). Exposure of cells to 1-100nM MBP increased the expression of both ESRRA 
(significantly induced, p<0.05, at 1, 10, 100nM) and ESR2 (1.32±0.07 fold increase at 
100nM exposure, p<0.01). ERRα is a major control point for oxidative metabolism in many 
cell types, including T cells.  Following exposure to both BPA and MBP, we found that cells 
showed a decrease in  proliferation rate. Taken together, these results confirm the bioactivity 
of BPA against putative T cell targets in vitro at concentrations relevant to general human 
exposure. 
 
Key words: Bisphenol A, endocrine disruption, estrogen receptor beta, estrogen-related 
receptor alpha, gene expression, T cells. 
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 List of any unusual abbreviations used in the manuscript: 
B2M, beta 2 microgloubulin 
BPA, bisphenol A 
ESRRA (ERRα), estrogen related receptor α 
ESR2 (ERβ), estrogen receptor β 
EE2, 17α-Ethinylestradiol  
FAM102A, family with sequence similarity 102 
FBS, fetal bovine serum  
HK, housekeeping genes 
HPRT1, hypoxanthine phosphoribosyl- transferase 1 
LOD, limit of detection 
MBP, 4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene 
NMR, nuclear magnetic resonance  
PPARγ, peroxisome proliferator-activated receptor-γ  
RT-PCR, reverse transcription polymerase chain reaction  
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 1. Introduction 
Bisphenol A (BPA) is a synthetic compound originally synthesised as an alternative to 
estrogen (Dodds and Lawson, 1936). It is used widely as a monomer in polycarbonate 
plastics and in the epoxy resins that line food and drinks containers and is one of the world’s 
highest production volume chemicals (Ritter, 2011). Leaching of BPA from food packaging 
into food and subsequent ingestion is a major route of human exposure, with additional 
exposures from dental sealants, inhalation of household dusts and dermal routes (Bailey and 
Hoekstra, 2011). This has led to ubiquitous exposure of the general population, with >95% of 
people showing detectable levels of BPA in their urine (Calafat et al., 2008; Galloway et al., 
2010; Vandenberg et al., 2010). 
There has been a level of controversy over the adverse health consequences of exposure to 
BPA. Recent studies have demonstrated that human and wildlife populations are exposed to 
levels of BPA capable of negatively impacting on reproductive, developmental and metabolic 
endpoints in different wildlife species and laboratory animal studies (Calafat et al., 2008; 
Vandenberg et al., 2010). In addition, an increasing number of epidemiological studies has 
now shown that general population exposure to BPA is associated with adverse health 
outcomes. BPA exposures were positively associated with endocrine changes in men 
(Galloway et al., 2010; Meeker et al., 2010) and with negative effects on immune function 
(Clayton et al., 2011). Positive prospective associations have been reported between BPA 
exposure and a range of reproductive and developmental conditions including recurrent 
miscarriage (Sugiura-Ogasawara et al., 2005) and externalising behaviour scores in the 
offspring of exposed mothers (Braun et al., 2011). Urinary BPA concentrations were 
associated with cardiovascular disease diagnosis in large scale cross-sectional (Lang et al., 
2008; Melzer et al., 2012a; Melzer et al., 2010) and longitudinal studies (Melzer et al., 
2012b).  
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 The plausibility of these associations and a comprehensive understanding of the risks posed 
by exposure to BPA are complicated by a lack of understanding of the mechanisms 
underlying its varied endocrine disruptive actions. Many of the physiological effects of BPA 
have been studied in relation to its widely reported activity as an estrogen agonist (Chapin et 
al., 2008; Lee et al., 2003). A number of additional receptor-mediated effects have been 
reported including anti-androgen activity (Bonefeld-Jørgensen et al., 2007), thyroid hormone 
disruption (Moriyama et al., 2002), altered pancreatic beta-cell function (Ropero et al., 2008; 
Soriano et al., 2012) and obesity promoting effects (Marmugi et al., 2012; Newbold et al., 
2007), binding to estrogen related receptor gamma (Okada et al., 2008; Takayanagi et al., 
2006) and activation of peroxisome proliferator-activated receptor-γ mediated pathways 
(Kwintkiewicz et al.). Comprehensive reviews of the available data highlight both the 
complexity of BPA’s biochemical and molecular interactions, and that these varied receptor 
systems and molecular pathways may be differentially affected in different target tissues and 
species (Thayer and Belcher, 2011; Wetherill et al., 2007). 
In order to gain a better understanding of the molecular mechanisms underlying the health 
effects of BPA, we recently studied the in vivo expression of a panel of estrogen receptor-
estrogen-related receptor and androgen receptor genes in the peripheral blood leukocytes 
taken from 96 adult men (Melzer et al., 2011). We found that there were positive associations 
between higher BPA concentrations and higher expression of 2 genes, ESR2 (estrogen 
receptor 2, ERβ) and ESRRA (estrogen related receptor alpha, ERRα). This finding is of 
interest since it suggests that BPA and/or its metabolites are bioactive in the human body and 
that associations with hormone signalling and related disorders are biologically plausible. 
ERβ is important in mediating the physiological actions of estrogens in target tissues 
including prostate, colon, cardiovascular and central nervous systems (Imamov et al., 2005), 
with a tissue distribution and ligand specificity that is distinct from that of ERα. ERRα 
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 belongs to the NR3β orphan nuclear receptor family subgroup, consisting of ERRα, β and γ. 
Although responsive to some synthetic estrogens, there are no known naturally occurring 
ligands for ERRα (Willy et al., 2004). Genetic studies in mice show that ERR subtypes are 
involved in mitochondrial biogenesis, oxidative phosphorylation and lipid metabolism 
(Tremblay and Giguere, 2007). Both ERRα and γ are essential for proper cardiac function 
(Huss et al., 2007) and may play a broader role in metabolic homeostasis (Tennessen et al., 
2011). The functional relevance of changes in ERβ and ERRα in blood leukocytes has not 
been comprehensively determined, although ERRα is reported to be a selective 
transcriptional regulator of certain T cell effector functions, facilitating gene expression and 
glucose and mitochondrial metabolism during T cell growth and proliferation (Michalek et 
al., 2011). 
 
The objectives of the current study were to explore the expression of the ESR2 and ESRRA 
genes in human leukaemic T cell lymphoblasts (Jurkat cells) exposed to BPA in vitro. In 
addition, we investigated the effect of  a putative metabolite of BPA: oxidative metabolism of 
BPA by rat or human liver S9 fractions yields the potent estrogenic metabolite 4-methyl-2,4-
bis(4-hydroxyphenyl)pent-1-ene (MBP), which has around 1000 fold higher estrogenic 
activity than BPA (Okuda et al., 2010). 3D models of MBP suggest that its structure allows 
for interaction with amino acid residues in ERα and ERβ that are important for binding of 
estradiol by these receptors (Baker and Chandsawangbhuwana, 2012) We compared the 
expression of ERβ and ERRα following exposure to 17α-Ethinylestradiol (EE2), BPA and 
MBP at environmentally relevant exposure concentrations and over different time intervals. 
Since ERRα is a major control point for oxidative metabolism in many cell types, including T 
cells, we determined the effects of BPA and MBP exposure on the downstream end-point of 
cell proliferation.  
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2. Material and Methods 
2.1 Synthesis of 4-methyl-2,4-bis (p-hydroxyphenyl) pent-1-ene (MBP). MBP was 
synthesized at Hiroshima International University as previously described (Yoshihara et al., 
2004). MBP was in the form of a white powder with melting point 130.5-132ºC; purity was 
certified from the narrow melting point range obtained and the single peak obtained by 
HPLC. The 1H NMR data (400MHz, CDCl3) of authentic MBP obtained using a JEOL, 
ALPHA-FT NMR Spectrometer,was: δ 1.20 (s,6H), 2.74 (s,2H), 4.64 (s, 1H), 4.71 (d, 1H,Ј = 
2.0Hz), 4.74 (s,1H), 5.07 (d,1H, Ј= 2.0Hz), 6.67(d,2H, Ј=8.8Hz),6.67(d,2H, Ј =8.4Hz), 7.09 
(d,2H, Ј =8.8Hz), 7.12 (d,2H, Ј =8.8Hz). Chemical shifts are reported in ppm downfield from 
the peak of tetramethyl-silane (TMS) used as an internal standard. Splitting patterns are 
designated as "s and d" indicating "singlet and doublet", respectively. 
 
2.2 Cell culture, dosing and exposure. All further experiments were conducted at the 
University of Exeter. Jurkat cells, human leukaemic T cell lymphoblasts, were purchased 
(catalogue number: 88042803) and cultured in RPMI-1640 without phenol red (Sigma-
Aldrich Company Ltd., UK), supplemented with 10% fetal bovine serum, FBS, stripped with 
charcoal-dextran (Gibco, Gran Island, NY) and 200mM L-glutamine (Sigma-Aldrich). Jurkat 
cells were considered a good model system for several reasons. Firstly, our population level 
study (Melzer et al., 2011) was carried out on whole blood, therefore the choice of a 
lymphocyte cell line in which to investigate our findings further seems appropriate. Secondly, 
BPA exposure is known to have effects on cytokine production in T-cells in vitro (Yan et al., 
2008). Finally, ERRα, has many functions, including modulation of the immune response 
(Ranhotra, 2012). Cells were grown in suspensions at 37ºC- 5% CO2 and culture was 
maintained between 0.5-5 x 100.000 cells/ml. Before the experiments, cells were grown in a 
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 single tissue culture flask, angled neck vent cap, and then used for the experiment at passage 
3. Medium was changed ahead of the start of each experiment and it was not changed during 
the treatments. Cell viability was assayed with Trypan blue (Sigma-Aldrich) staining 
(dilution: 1/10th of 100µl culture volume). Cell viability was always above 80%. Cells were 
exposed to 17α-Ethinylestradiol (EE2; ≥98%, Sigma-Aldrich), Bisphenol A (BPA; ≥99%, 
Sigma-Aldrich) and to the oxidative metabolite of BPA, 4-methyl-2,4-bis (p-hydroxyphenyl) 
pent-1-ene (MBP), synthesised as described above. 
2.3 Exposure to EE2. Cells were equally divided into 36 small flasks (25 cm2) and each flask 
was considered as a single sample. Each flask was assigned to either the control or the 
exposed group: 1 µM EE2 and the solvent control (0.001% ethanol) were added accordingly. 
Total RNA extraction was performed at time point 0 hour, 6 hours (hrs), 24hrs, 36hrs, 48hrs, 
72hrs. The choice of these time points aimed at providing a very comprehensive description 
of the time dependent activation of the target genes across a time interval of 3 days. The 
selection of a time window of 72 hours was based on previous studies present in the literature 
(Naciff et al., 2010; Richter et al., 2007). During each time point 3 flasks from the control and 
the exposed group were randomly selected, sampled for RNA extraction and then discarded. 
2.4 Exposure to BPA and MBP. Jurkat cells were divided into treatment and control flasks, 
1µM BPA and solvent control (0.001% ethanol) were added accordingly. Cells were then 
seeded onto 24-well plates. Total RNA extraction was performed at time point 0 hour, 6hrs, 
24hrs, 36hrs, 48hrs, 72hrs. When exposures of 1 nM, 10 nM and 100nM BPA concentrations 
were then tested, mRNA expression was measured at a single time-point (72hrs). The 72hrs 
time-point was considered a sensitive window based on the results of the 1µM BPA 
experiment. Treatments and solvent controls were added accordingly to the different 
concentrations as previously described. Treatments were replicated in 8 wells per experiment 
and the control in 6. Two parallel experiments were conducted; results were checked for 
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 statistical differences, then tabulated and merged. Similarly, a set of experiments was 
performed exposing cells to MBP that was tested at 1nM, 10 nM, 100nM concentrations. 
Study design, replication and sampling time were as the ones described above. 
2.5 Real time RT-PCR measurement of gene expression in target genes. Total RNA was 
extracted after sampling using the RNeasy Mini Kit from Qiagen according to the 
manufacturer’s instructions. RNA yield was quantified using a NanoDrop spectrophotometer.   
Total RNA (500ng) was reversed transcribed in 20μl reactions using the Superscript III VILO 
kit (Invitrogen, Paisley, UK). Real time PCR amplifications were performed on the ABI 
7900HT platform using 96-well plates (Applied Biosystems, Foster City, USA). Each well 
contained 5µl TaqMan 2x universal master mix (no AMPerase) (Applied Biosystems, Foster 
City, USA), 3.5µl dH2O, 1µl cDNA template and 0.5µl of probe. Cycling conditions were 
50°C for 2 minutes, 95°C for 10 minutes followed by 50 cycles of 95°C for 15 seconds and 
60°C for 1 minute. The expression levels of the genes ESR2 (estrogen receptor 2; ER beta; 
ERβ), and ESRRA (estrogen related receptor alpha; ERRα) were assessed through relative 
quantification using the 2–ΔΔCt method (Livak and Schmittgen, 2001). Data are presented as 
the fold change in gene expression relative to 3 endogenous control transcripts and 
normalised to levels of the test transcripts in the untreated control. PCR signal of the target 
transcripts was standardized using three housekeeping (HK) genes: B2M (β2 
microgloubulin), HPRT1 (hypoxanthine phosphoribosyl-transferase 1) and FAM102A (family 
with sequence similarity 102). This was done to account for differences in the amount of 
cDNA that is loaded into each PCR reaction wells and differences between plates. The 
expression of each of the five genes was measured in triplicate for each sample: this technical 
procedure provides a more accurate PCR analysis, for it helps removing technical errors or 
highlights weak and variable signals. A minimum of three HK genes is recommended for a 
reliable standardization factor and to reduce errors in real-time quantitative RT-PCR data 
56 
 
 (Vandesompele et al., 2002). B2M and HPRT1 are widely used HK genes (Vandesompele et 
al., 2002) while FAM102A expression was shown empirically not to be influenced by BPA 
exposure in our previous experiments. Probes were inventoried Applied Biosystems assays, 
with the exception of the ESRRA probe, which was a custom assay (probe and primer 
sequences available on request). 
2.6 Cell count. Cell count was carried out using the particle counting Multisizer Coulter 
Counter (Beckman, USA).  
2.7 Statistical analysis. Values in tables and graphs are expressed as mean ± SEM (unless 
otherwise specified). Two-way factorial ANOVA was used to test the interaction between 
treatment and time of exposure when multiple time-points were considered. Data were 
checked for the normality of distribution and variance homogeneity. Where the overall 
ANOVA showed significance, post-hoc comparisons between treatment and its control were 
performed. When only the effect of different treatments was tested, one-way ANOVA was 
used followed by Bonferroni post-hoc test. p-value <0.05 was considered significant. 
 
3. Results 
3.1 Time and dose responsiveness of ESR2 and ESRRA in Jurkat cells. All target genes 
(ESR2, ESRRA) and HK genes (B2M, HPRT1, FAM102) were empirically checked and 
consistently detected in Jurkat cells. The estrogen responsiveness of cells was initially tested  
using 17α-Ethinylestradiol (EE2) (Naciff et al., 2010). A time dependent increase in 
expression of both ESR2 and ESRRA target gene transcripts was seen (Figure 1A and 1B) 
following exposure to 1μM EE2. For ESR2, a monotonic increase was seen, with maximum 
intensity of expression at 72h and indication of an increasing trend (Figure 1A). On the other 
hand, ESRRA showed a biphasic trend with a non-significant increase in gene expression after 
6 hours, a subsequent drop, and a significant increase at 48 and 72 hours (mean±SEM, up to 
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 2-fold increase +/- 0.09 compared to the control, p<0.05). Exposure to 1μM BPA under the 
same conditions produced a similar level of increase (Figure 1C and 1D). The time profile of 
BPA exposure indicates that ESR2 expression was significantly induced compared to the 
control after 36 hours (1.36±0.10 fold increase, p<0.05). Expression of ESRRA again showed 
a biphasic response: a statistically significant increase was registered after only 6 hours of 
exposure to BPA followed by a drop at 24 hours and a second significant increase at 48 hours 
(1.58±0.08 fold increase, p<0.01 remaining elevated for the duration of the experiment. 
Overall, exposure to a high concentration of BPA showed a stronger and quicker increase in 
mRNA expression levels of ESRRA than ESR2. 
Exposures were then conducted at environmentally relevant concentrations (1nm – 100nm) of 
BPA (Figure 2A-B). Similar concentrations were selected in the MBP experiments (Figure 
2C-D). The ESR2 mRNA expression level did not change in treatment groups exposed to 
increasing concentrations of BPA (Figure 2A). There was however a significant increase in 
ESR2 expression following 72h exposure to 100nM MBP: the average value in the treatment 
group (mean± SEM, 1.32±0.075, n=16) was significantly higher than the control group 
(1.01±0.046, n=12, Figure 2C). For ESRRA, significantly increased expression was seen 
following exposure to both BPA and MBP at all concentrations from 1nM upwards (Figure 
2B and 2D). Jurkat cells exposed to increasing concentrations of BPA showed levels of 
ESRRA expression increased by up to 82% (± 13%, n=16). Similar results were registered 
after exposure to MBP (Figure 2C and D). 
3.2 Effects of BPA and MBP on cell proliferation. Jurkat cells exposed to 100 nM BPA 
showed a decreased number after 48 hours compared to the control (Figure 3A). After 72 
hours, the difference in cell count between exposed and control groups was greater 
(p<0.001). Similarly, Jurkat cells exposed to 100 nM MBP showed a decreased proliferation 
after 48 and 72 hours (Figure 3B).   
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4. Discussion 
We have previously reported that human exposure to BPA is associated with the activation of 
the estrogen responsive genes ESR2 and ESRRA measured in peripheral blood leukocytes in 
the general adult population (Melzer et al., 2011). The ERs and ERRs share common targets 
and control overlapping transcriptional regulatory networks. This makes them of high interest 
for investigating the effects of BPA and related compounds showing diverse, estrogen-like 
effects. The aim of this study was to further explore the expression of ESR2 and ESRRA in 
human leukaemic T cell lymphoblasts exposed to BPA under laboratory conditions where 
potentially confounding variables could be controlled. We show here that BPA and the 
oxidative derivative MBPat environmentally relevant concentrations can cause changes to 
hormone sensitive gene transcripts and that this has physiological consequences in altering 
cell proliferation rate in T cells. This is important because these results, taken together with 
our previous study, suggest that ESRRA gene expression can be significantly modulated by 
BPA in human blood cells, both in laboratory and in vivo conditions; hence, imply that BPA 
is capable of plausible bioactivity in the human body.  
 
Of particular interest is what we believe to be the first report of a significant increase in 
expression of ESRRA following exposure to both EE2 and BPA in T cells. ERRα is a 
regulator of cell metabolism across many different cell types (Giguère, 2008; Villena and 
Kralli, 2008) and has a central role in regulating energy homeostasis and adaptive oxygen 
capacity. Activity of ERRα, which has no known endogenous ligands, is known to be 
regulated at the protein level; activity is highly sensitive to co-regulatory proteins involved in 
energy homeostasis such as the steroid receptor co-activator (SRC), peroxisome proliferation 
activation receptor gamma co-activators (PGC)-1α/β and the co-repressor receptor-interacting 
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 protein 140 (RIP140). Our data show additional regulation at the level of the messenger 
RNA, indicating both  the importance of transcriptional regulation (Giguère, 2008) and 
highlighting a novel target for the action of endocrine disrupting chemicals in the body.  
 
The activity of ERRα as a transcriptional regulator in T cells has recently been described in 
detail (Michalek et al., 2011). T-cell activation and differentiation are energetically 
demanding processes and considerable metabolic reprogramming is required to enable the 
rapid proliferation and functional responsiveness of T effector (Teff) and repressor (Treg) cell 
subsets. Accordingly, ERRα appears to play a key role in Teff cell function through the 
induction of metabolic gene expression to programme mitochondria for aerobic glycolysis 
and to regulate glycolytic metabolism more generally. Interference in this process by BPA 
could in theory alter the balance of Teff and Treg cells, leading to immunotoxic effects. 
Although the full significance of ERRα expression in the Jurkat lymphoblastic cell line that 
we have used here is not yet known, we were able to show a significant inhibition of cell 
proliferation following exposure to 100nm BPA, consistent with this theory. 
There may be some factors to consider when interpreting this result. Given the fact 
that these were not primary cells, senescence should not affect Jurkat T cells. Cell viability 
was checked before the experiment using Trypan blue assay that is a dye exclusion test used 
to determine the number of viable cells present in a cell suspension. Yet, we did not perform 
an analysis relative on the cell cycle arrest which could be an early sign of cell apoptosis.  
It would be of considerable interest to determine the effects of BPA on ESRRA expression 
and metabolic activity in a wider range of different cell types, especially in light of the 
associations previously reported between exposure to BPA and metabolic disease (Melzer et 
al., 2012a; Melzer et al., 2012b). ERRα is present in a wide variety of cell types and is highly 
expressed in cells with elevated metabolic demand such as heart, skeletal muscle and brown 
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 adipose tissue tissues (Eichner and Giguère, 2011). It is suggestive to note that BPA has 
shown affinity for the metabolic regulator peroxisome proliferator-activated receptor-γ 
(PPARγ) in a previous study (Kwintkiewicz et al., 2010) and in addition there is evidence of 
agonist interaction between PPARγ and ERRα  (Willy et al., 2004) and PPARγ and ERβ 
(Foryst-Ludwig et al., 2008). More recently, Marmugi et al (2012) used a transcriptomic 
approach to show that exposure of male CD1 mice to low doses of BPA was able to influence 
de novo fatty acid synthesis through alterations in lipogenic genes. These results suggest that 
the role of BPA in influencing metabolic processes is certainly deserving of further attention. 
 
BPA metabolism and excretion are believed to take place largely in the first 24hrs after 
exposure, although there are studies suggesting this could take longer (Christensen et al., 
2012; Sieli et al., 2011; Stahlhut et al., 2009). After liver metabolism, glucuronide conjugated 
BPA shows little or no affinity for nuclear receptors (Matthews et al., 2001). In human 
biomonitoring studies, analyses performed on blood, serum, or plasma samples measured 
unconjugated BPA which is considered the portion of BPA not yet metabolised by the liver 
and so capable of bioactivity. A recent review of these studies indicates that the range of 
blood/serum BPA concentrations spans between 0.5 and 2.5 ng/ml (Vandenberg et al., 2010). 
Given the range of concentrations chosen for our experiments (1-10nM; 1nM BPA = 0.228 
ng/ml), we could argue that this reflects very well the physiological internal exposure to 
unconjugated BPA. The same range of concentration has been taken as reference in other 
major experimental studies (Hugo et al., 2008; Richter et al., 2007), whilst a recent review of 
human toxicokinetic studies suggests the circulating concentration may be lower than this 
(Doerge and Fisher, 2011).  
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 Oxidative cleavage of BPA to form the estrogenically active metabolite MBP was first 
reported in rat liver and Okuda (Okuda et al., 2010) reported that MBP was 500 fold more 
potent than BPA in inducing dose –dependent changes in expression of ESR1 and ESR2 
mRNA. Here, we have shown a small but significant up-regulation of ERβ following 
exposure of cells to 100nM MBP, which would agree with an enhanced estrogenic activity of 
this compound. In addition, MBP showed a near identical pattern of up-regulation of ESRRA, 
with a significant increase in expression seen at concentrations as low as 1nM. The full 
significance of this metabolite in humans is not yet known. MBP is formed by recombination 
of the radical fragment of BPA, and its formation requires both microsomal and cytosolic 
fractions. A similar mechanism of metabolism has been reported in sewage sludge bacterial 
isolates (Spivack et al., 1994).  Whilst the glucuronate/sulphate conjugates are the main 
metabolites excreted in urine, a comparison of phase 1 metabolism in human and rat liver 
microsomes has identified the oxidation product BPA-catechol as a minor metabolite 
(approximately 10%) in both species, and BPA-catechol is certainly measurable in human 
urine (Ye et al., 2011). Since BPA-catechol itself is also reported to possess estrogenic 
activity, further investigation of the pathways of BPA metabolism and related compounds in 
humans would seem to be a priority for future research. 
 
5. Conclusions 
We provide here a first report of the enhanced expression of two estrogen responsive genes, 
ESR2 (ERβ) and ESRRA (ERRα) in human leukaemic T cell lymphoblasts exposed to BPA at 
concentrations relevant to general population exposure. Significantly enhanced expression of 
both of these transcription factors in vivo has previously been associated with exposure to 
BPA in peripheral white blood cells in adult men (Melzer et al., 2011). Since ERRα is a 
major control point for oxidative metabolism in many cell types, including T cells, we also 
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 determined the effects of BPA and MBP exposure on cell proliferation and showed a 
significant inhibition at nanomolar concentrations of both compounds.  These results add to 
the weight of evidence for how BPA is able to exert significant biological effects at chronic 
low levels of exposure and identify a novel metabolic target for the action of endocrine 
disrupting chemicals.  
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 Figure 1. Gene expression intensity as a function of time following exposure of Jurkat cells to 1µM EE2 (A and B) or 1µM BPA (C and D). 
Values are expressed as fold-change increase compared to each time-point control (mean ± SEM). The number of replicates is shown in each bar  
(* when p<0.05).   
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 Figure 2. Gene expression intensity after 72 hours exposure of Jurkat cells to 1nM-10nM-100nM BPA (A and B) or 1nM-10nM-100nM MBP (C 
and D). Values are expressed as fold-change increase compared to control (Ctrl). Box plots follow Tukey’s rules and outliers are represented by 
dots (see D).Number in brackets is the number of replicates. (* when p<0.05)   
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 Figure 3. Proliferation rate decrease (A and B) in Jurkat cells exposed to 100nM BPA and 100nM MBP after 48 and 72 hours compared to 
control. Values are expressed as mean±SEM. The number of replicates is shown in each bar.. p-values are reported above the bars when p<0.05. 
 
 
6 6 10 10
0
50
100
150
200
250
300
350
C
el
ls
 n
um
be
r (
x 
10
00
)
48hrs 72hrs
Ctrl BPA 100nM
6 6 10 10
0
50
100
150
200
250
300
350
C
el
ls
 n
um
be
r (
x 
10
00
)
48hrs 72hrs
Ctrl MBP 100nM
p= 0.00001  
  
 p= 0.0005  
  
 
p= 0.0003  
  
 
p= 0.033  
 
  
73 
 
 5. Long Term Stability of Urinary Bisphenol A Concentrations in a 
European Adult Population 
 
5.1 Statement of the candidate's contribution to the co-authored paper. 
The candidate had full access to all of the data in the study and was responsible for the 
statistical analysis: descriptive statistics, data tabulation, analyses of the association 
between uBPA concentration and parameters in the InChianti dataset, drafting of the 
manuscript were carried out during the second and third year of the research 
programme. Analysis and interpretation of the results were discussed with Prof. T. 
Galloway and Prof. D. Melzer who were responsible for the study design, the accuracy 
of the data analysis, and the drafting and critical revision of the paper.  
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 Abstract 
Bisphenol A (BPA) is a high production volume chemical with widespread exposure. 
Epidemiologic studies suggest associations with health outcomes, although these largely 
rely on urinary BPA (uBPA) concentrations measured at single time points. Little is 
known about the variability of uBPA concentrations over long time periods. Here we 
aim to compare uBPA concentrations measured in 218 participants (aged 32-75 years) 
of the InCHIANTI longitudinal study at baseline (1998-2000) and nine years later 
(2007-09), and to identify characteristics associated with uBPA concentrations.  
Geometric mean baseline uBPA was 3.87 ng/ml (range 0.53 to 20.78 ng/ml) and 
slightly lower nine years later (3.17 ng/ml, range <0.5 to 29.63 ng/ml). Within subject 
logged uBPA concentrations were correlated (r=0.58; p=0.013, model adjusted for age, 
sex, urinary creatinine). Subjects in the top quartile (4th) of uBPA distribution at 
baseline were, nine years later, still in the top 3rd or 4th quartile in 70% of cases. Among 
possible predictors of BPA exposure, age and alcohol consumption were the two most 
consistently associated to uBPA throughout the period investigated.   
These results show that uBPA concentrations can be relatively stable over lengthy 
periods, and hence adds to the plausibility that reported associations with health 
outcomes may be causal. 
 
Key words: bisphenol A, endocrine disruption, human biomonitoring, health effects, 
inchianti study, stability.  
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 Introduction 
Bisphenol A (BPA) is one of the highest volume chemicals produced worldwide with an 
annual production of 8 billion pounds. Used as a plastic monomer and plasticizer, BPA 
is found in numerous consumer products and a number of studies have detected BPA 
leaching into foods (1). Since BPA has demonstrated endocrine-modulating ability in 
laboratory and population studies, there are concerns that the amount of BPA to which 
humans are exposed may cause adverse health effects.  
There are now a number of studies showing associations between exposure to BPA and 
health conditions in the general population (2-7). Using data from the U.S. National 
Health and Nutrition Examination Survey (NHANES) for 2003–2004 and 2005–2006, 
we showed for the first time an association between BPA exposure and cardiovascular 
disease, type 2 diabetes in people aged 18 to 74 years old (8, 9). Similarly, our recent 
longitudinal study in healthy adults of the Norfolk-EPIC study followed for up to 10 
years showed that higher uBPA concentrations predicted coronary artery disease onset 
(10).  
The results from these and other human biomonitoring studies have attracted the 
attention of regulatory agencies. The correct estimation and the association of human 
exposure to BPA and related health outcomes are subject of debate (11). Currently, the 
matrix of choice for such studies is urine, since orally ingested BPA is rapidly 
metabolised via hepatic glucuronidation and excreted via the kidneys. Spot samples 
remain the most practical method of choice for large scale biomonitoring and are the 
regulatory methods of choice (12). However, there remain knowledge gaps in our 
understanding of how a single spot urine sample may be representative of chronic 
exposures. Due to the short biological half-life of BPA, it has been suggested that only 
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 24 hours urine measurements could account for considerable within-day variation in 
subjects.  
Moreover, given the long latency period of the health outcomes associated with BPA 
exposure, such as cardiovascular disease and diabetes, any measure of exposure should 
be reasonably stable over several years, or perhaps decades.  
A few studies on temporal stability of BPA exposure have been published but focused 
on intervals of days or a few weeks (13-19). To the best of our knowledge, no 
longitudinal studies on a general population have been designed to study long term 
variability of uBPA over long time periods.  
Given these uncertainties, we set out to explore the temporal stability of urinary BPA 
concentrations measured across longer time intervals (9 years). We recently published a 
new study on a European population, the InChianti longitudinal study (5), in which at 
baseline (1998-2000) participants were requested to collect urine for 24 hours; this was 
the first study to address questions on BPA measurement methods and the 24h exposure 
to BPA. Also, participants completed a questionnaire on daily food intake: food is 
considered a primary source of BPA exposure and changes in diet are believed to be 
reflected in variations of uBPA levels.  
Here we present data on concentrations of uBPA measured in 218 subjects (aged 32 to 
75) who took part in both the baseline study and the 9 year follow-up. Participants 
provided a 24 hour urine specimen at baseline (1998-2000) and a single-spot specimen 
at follow-up (2007-09). Therefore, we aimed to provide indications of changes in BPA 
exposure in a general population along a 9-years time window. We also examined the 
association between uBPA concentrations and possible predictors such as age, sex, 
BMI, socio-economic condition, and alcohol consumption.  Because BPA is often used 
as a monomer in epoxy resins that are used to line food and beverage containers, we 
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 investigated whether changes in uBPA concentrations across the period considered were 
associated with changes in canned food and soda drinks consumption. 
 
Materials and Methods 
Study population. The InCHIANTI study (http://www.inchiantistudy.net/study.html) 
was designed to identify risk factors for mid- and late-life morbidity and was conducted 
in the Chianti area (Tuscany) of Italy. Participants were originally enrolled in 1998-
2000 (Baseline), and consented to collect urine for 24 hours. Subjects were then seen 
every three years and provided single-spot urine specimens. Levels of 24h uBPA were 
measured at baseline in 720 adults (aged 20 through 74 years), a subset of the full 
cohort. Details have been previously described (5). The recent 9-year follow-up exam 
(3rd wave) was carried out in 2007-09: we analysed uBPA concentrations in 264 
subjects selected randomly between the 309 participants (aged 75 or younger) who 
consented to give urine specimen (Table 1). The number of subjects with uBPA 
concentrations measured both at baseline and 3rd wave was 220. Two subject with 
extremely high value of uBPA (>50 ng/ml) in the 3rd wave were dropped, this left 218 
participants. 
Analysis of urinary BPA concentrations. Analysis of samples was performed at the 
Brixham Environmental Laboratory Division of Analytical Chemistry (a division of 
AstraZeneca PLC) in compliance with Good Laboratory Practice, EU Directive 
88/32/EEC. To measure total (free and conjugated) urinary concentrations of BPA, we 
used the methods employed by NHANES and adopted by the Division of 
Environmental Health Laboratory Sciences, National Center for Environmental Health, 
Centers for Disease Control and Prevention to prepare the urine samples (20). Analyses 
where carried out using online solid-phase extraction (SPE) coupled with high-
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 performance liquid chromatography (LC)–isotope dilution tandem mass spectrometry 
(MS/MS) with peak focusing. This has been described more extensively elsewhere (5). 
The limit of detection (LOD) was 0.5 ng/ml. At Baseline, no observation was below 
LOD; in 2007-09, two observations were <LOD and a value of 0.28 ng/ml was assigned 
instead, as in our previous studies (8, 9). In 2007-09, uBPA concentrations were 
measured in single-spot urine samples: in order to account for urine dilution, we used 
creatinine adjustment and measures of urine specific gravity (SG). Urinary creatinine is 
often used to adjust for urine dilution in single-spot uBPA measurement (20). Similarly, 
SG has been used in other studies as an alternative to creatinine correction (3, 14). Since 
baseline uBPA measurements were based on 24hrs urine collection, no urine dilution 
adjustment was considered when we analyzed baseline data.  
BPA potential exposure predictors and demographic covariates. Participants received 
a food questionnaire originally developed and validated in the European Prospective 
Investigation into Cancer (EPIC) and were followed by trained interviewers (21). 
Initially, analysis on the association between uBPA concentration and single food items 
consumption was carried out at baseline where 300 variables were available. The same 
was done in the 3rd wave. This initial approach resulted in two major problems: the 
necessary multiple testing adjustments allowed comparison only with very low p-
values; although extensive, the questionnaire provided little information on food 
packaging, or any other characteristics that could link food to potential BPA exposure 
through contact, hindering the interpretation of the results. For this reason, in addiction 
to common demographic covariates, we decided to include in our analysis only food 
variables which could be related to BPA exposure through packaging contact. Since 
BPA is often used as a monomer in epoxy resins that are used to line food and beverage 
containers (22), we considered information on canned meat and canned fish 
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 consumption (frequency of canned meat/fish eaten per day). Both variables were 
analyzed and then considered together as “canned food” consumption. Similarly, 
carbonate, isotonic and soda drinks consumption (frequency per day) was included in 
the analyses because often linked to BPA exposure (23). Participants declared how 
many time per day they drink wine, beer and spirits. This information was summed into 
one single variable defined as alcohol consumption. Alcohol consumption was 
calculated as frequency of drinks per day. Participants were requested to define annual 
income as “adequate”, “barely adequate”, or “inadequate”. Smoking habits were 
classified as “never”, “former”, and “current” smoker. BMI was tested as a continuous 
variable and as a categorized variable with subjects divided in underweight (< 18.5 
kg/m2), recommended weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), obese 
I (30.0–34.9 kg/m2), and obese II (≥ 35 kg/m2) categories.  
Statistical analyses. Descriptive statistics of uBPA concentrations from baseline and 3rd 
wave analyses were tabulated. Correlation with demographic variables was tested and 
graphically examined. Because uBPA has a skewed distribution, values were log 
transformed in regression analyses. Linear regression models were adjusted for age and 
sex and then separately for creatinine and SG. Because baseline uBPA was measured in 
24-hours collection samples, creatinine and SG adjustment was considered appropriate 
only for single-spot uBPA (3rd wave). Creatinine measurements were available for 186 
specimens whereas SG levels were available for 214. Spearman correlation was 
calculated between differences in uBPA across the two analyses and differences in 
BMI, income, canned food intake, alcohol and soft drinks consumption from 1998 to 
2007.  
81 
 
 We carried out a set of sensitivity analysis to test the robustness of our findings, and 
correlation between uBPA measurements was reassessed considering changes in alcohol 
consumption and other predictors of uBPA concentrations, from 1998-00 to 2007-09.  
 
Results 
Urinary BPA concentration was measured in samples from the InCHIANTI baseline 
(1998-2000) when subjects were requested to collect the urine produced in 24 hours. 
Single-spot uBPA concentrations were then measured approximately nine years later, 
during the 3rd wave of the study (2007-09). Demographic characteristics of the 
participants are summarized in Table 1. The age (mean ± SD) at the baseline was 48.9 ± 
14.4 years; there were equal numbers of males (109) and females (109). Baseline and 3rd 
wave uBPA concentrations are presented in Table 2. At baseline, geometric mean uBPA 
was 3.87 ng/ml (95% CI 3.57 to 4.19). The distribution was skewed, with a 10th 
percentile of 1.9 ng/ml, a median of 3.8 ng/ml, and a 90th percentile of 7.9 ng/ml. In 
2007-09, geometric mean uBPA was 3.17 ng/ml (95% CI 2.84 to 3.55). BPA 
distribution remained skewed, with a 10th percentile of 1.2 ng/ml, a median of 2.96 
ng/ml, and a 90th percentile of 9.6 ng/ml. In Table 2, age and gender difference appear 
as predictors of uBPA levels. Levels of uBPA were higher in men than women in 1998-
00 and 2007-09. Urinary BPA concentrations followed a clear negative age trend both at 
baseline and 3rd wave (Figure 1).  
Stability over 9 years. Baseline logged uBPA concentrations were significantly 
correlated with the 9-year follow-up measurements in a linear regression model adjusted 
for age and sex (n=218; r =0.40; β=0.3040, 95% C.I. 0.1354-0.4726; p<0.001). In age, 
sex and urinary creatinine adjusted models, associations between uBPA measurements 
increased (n=186; r=0.57; β=0.2063, 95% C.I. 0.0411-0.3716; p=0.015). A third model, 
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 adjusted to age, sex and urine specific gravity (SG) provided no substantive changes 
compared to the previous model (n=214; r=0.59; β=0.1784, 95% C.I. 0.0216-0.3352; 
p=0.026). In Figure 2, we show the log values scatter plot of baseline and 3rd wave 
uBPA measurements.  
We also examined associations between uBPA baseline and 3rd wave quartile 
distributions: overall, subjects classified in the top quartile (4th) of uBPA distribution at 
baseline were, nine years later, still in the top 3rd or 4th quartile in 70% of the cases. 
Similarly, the proportion of subjects in the 1st quartile at baseline that were still in the 1st 
or 2nd quartile nine years later was 65%.    
Factors associated with changes in uBPA concentrations. We then investigated 
whether participants with large differences in uBPA from baseline to follow-up also 
reported changes in possible predictors of uBPA exposure. Initially, main covariates 
such as BMI, socio-economic condition, alcohol consumption, canned food and soft 
drink consumption were fitted in regression models to test for association with uBPA 
log values across the two examinations. Concentrations of uBPA were positively 
associated with alcohol intake in participants of baseline and 3rd wave analyses (Table 
3). At baseline, uBPA levels were positively associated to carbonate, isotonic and soda 
drinks consumption (β=0.150, p=0.031). This association was not confirmed 9 years 
later although the number of participants was far smaller. We then tested the association 
between differences in uBPA concentrations and variations in main covariates across 
the two analyses; in models adjusted for all main covariates and food variables, changes 
in daily alcohol consumption were positively associated with differences in uBPA from 
baseline to follow-up (β=0.104, p=0.029; Table 3). In simple correlation analysis the 
association was confirmed (Spearman correlation=0.174, p=0.011): a decrease in 
alcohol daily intake was associated to a decrease in uBPA concentrations; the same was 
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 true for increased alcohol and uBPA levels. Other food variables in the model were not 
associated with changes in uBPA concentration, only changes in canned food 
consumption were nearly significantly associated (Table 3).    
 
Sensitivity analyses. We reran our models of uBPA stability, previously used to assess 
the correlation between the two uBPA measurements, adjusting also for changes in 
alcohol, soft drink, canned food, income and BMI across the two analyses. Given the 
higher number of variables fitted in the sensitivity analysis compared to the initial 
models, we used the adjusted-R2 coefficient to compare the results with the initial 
models. Correlation between baseline and 9 year logged uBPA increased in all three 
regression models, in particular when urine specific gravity was considered (n= 205, 
r=0.63, β=0.172, 95% C.I. 0.014-0.330; p=0.033). 
 
Discussion 
We report levels of uBPA measured in an adult community-dwelling population across 
a time interval of nine years. Previously, temporal stability of BPA exposure has been 
studied over short time periods only. In our study we show that 24 hour urine specimens 
at baseline did show reasonable correlation with spot logged uBPA concentrations 9 
years later. To the best of our knowledge, these are the first data on long-term temporal 
variability of uBPA concentrations, across several years, in a normal adult population.  
Two studies investigated uBPA concentrations in a cohort of women before and during 
pregnancy (17, 18), and indicated that BPA concentrations were variable before and 
during pregnancy. Childhood levels of exposure over 6 months were reported by 
Teitelbaum et al. (13), suggesting a reasonable degree of temporal stability. Given the 
unique features of the cohorts in those studies, conclusions may not be extended to a 
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 general population. Mahalingaiah et al. (14) investigated temporal variability of BPA in 
48 subjects over weeks and months and concluded that a single sample showed 
moderate sensitivity for predicting long-term exposure. Nepomnaschy et al. (19) 
measured urinary BPA concentration in first-morning samples from 60 premenopausal 
women over a period of 4 weeks and found that exposures were similar in the short term 
but became more variable at the end of the 4-weeks period. Other two studies 
investigated the within-person and within-day variability of uBPA concentrations 
during a 5/7-days examination in groups of 5 and 8 volunteers (15, 16). Both studies 
found a considerable variability in the period investigated. Still, no longitudinal studies 
on a general population have been designed to study the long term variability in uBPA 
concentrations.  
In this study we show that within-subjects uBPA concentrations were significantly 
correlated. Urinary BPA measurements were correlated in linear regression models 
adjusted for main covariates as well as models adjusted for indicators of urine dilution 
such as urinary creatinine and urine specific gravity. Although measurements were 
significantly correlated, the 218 subjects involved in both analyses had higher 
geometrical uBPA means at baseline than 3rd wave (Table 2 and 3). The higher values 
reported at baseline might be explained by an “age effect”: age is a clear predictor of 
uBPA concentration being negatively associated to uBPA in both analyses (see Figure 
1). A negative age-uBPA trend was a predictor of uBPA concentrations in two major 
cross-sectional biomonitoring studies, the NHANES 2003-04/2005-06 surveys (20, 24). 
Younger subjects generally have higher uBPA concentrations. A cause for the “age 
effect” is difficult to identify. Potential explanations for differences in uBPA 
concentrations include changes in routes of exposure (i.e. food and drink ingestion) or 
changes in BPA metabolism and/or excretion.  
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 Another strong predictor of uBPA exposure in our analysis was alcohol consumption 
(Table 3). Alcohol and uBPA were strongly positively associated in linear regression 
models, even when adjusted for main covariates, both at baseline and 3rd wave. This 
suggests alcohol consumption as a source of BPA exposure, possibly related to storage 
and packaging of alcoholic drink. BPA has been found leaking into canned alcoholic 
drink (25) and has been already associated to alcohol consumption in a biomonitoring 
study (26).   
A potential predictor of uBPA concentration in the InChianti study is gender difference. 
In both analyses, geometrical mean uBPA was higher in male than female (Table 2). At 
baseline, using 24-hours collection samples, sex was significantly associated with uBPA 
concentration in models adjusted only for age; no urine dilution correction was 
performed because of the collection method. Using single spot urine samples (3rd wave), 
sex was again significantly associated to uBPA concentration in model adjusted for age 
and major covariates (data not shown). Yet, this association disappeared when adjusting 
for urine dilution: both in SG adjusted model (Table 3) and creatinine adjusted model 
(data not shown). Similar to these findings, the NHANES 2003-04/2005-06 surveys 
reported analogous results (20, 24). It appears that gender difference is a less clear 
predictor of uBPA, influenced by urine dilution correction. 
We investigated other possible predictors of uBPA concentrations such as BMI, annual 
household income, canned food and soft drink consumption. None of these parameters 
was a statistically significant predictor of uBPA.  
 
Given the comparison of 24-hours with single-spot urine specimens, it can be claimed 
that this is a limitation for the study of uBPA temporal stability. While 24-hours urine 
collection is considered a gold standard for an accurate BPA measure in biomonitoring 
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 study, single-spot urine is regarded as less ideal, given human BPA metabolism and a 
short biologic half-life (27). It is interesting to note that, uBPA levels measured after 
single-spot urine collection showed the same trend in age and sex (in SG unadjusted 
models) distribution as for the 24h analysis.  
In conclusion, we have shown for the first time that uBPA concentrations can be 
relatively stable across lengthy time intervals. Associations between single time point 
urinary BPA concentrations and health outcomes may be the result of relatively stable 
long term repeat exposures to BPA. Changing urinary BPA concentrations are 
positively correlated with changes in alcohol consumption. 
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 Table 1. Demographic characteristics of participants:  
 
InChianti Study Characteristics Baseline (1998-00) 3rd wave (2007-09) 
Number of participants  
(≤75yrs) 959 336 
Lost to follow-up (≤75yrs) 
Refused Home Interview 
Emigrated 
Deceased 
 
24 
13 
13 
 
Number of participants providing urine specimens 
(≤75yrs) 912 309 
Urine specimens (%) analyzed  84.3 % 85.4 % 
Number of samples <LOD uBPA 0 2 
Participants in both analyses  
≤75yrs during the 3rd wave 218 
Baseline - 3rd wave interval (mean ± SD)  3339 ± 83 days  
Age (mean ± SD) 48.9 ± 14.3 58.2 ± 14.3 
Men 109 
Women 109 
BMI (mean ± SD) 26.6 ± 4.1 27.2 ± 4.6 
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 Table 2. Distribution of uBPA concentrations (ng/ml): 
 
Characteristics Geom. Mean (95% C.I.) No. of 
observation 
% 
All 
 
Baseline 3.87 (3.57 4.19) 218 - 
 
 
3rd wave 3.19 (2.86 3.55)   
Males 
 
Baseline 4.13 (3.66 4.66) 109 50.0 
 
 
3rd wave 3.54 (3.06 4.10)   
Females 
 
Baseline 3.61 (3.24 4.03) 109 50.0 
 
 
3rd wave 2.86 (2.44 3.37)   
Age group Baseline 
21 – 40 yrs 
3.93 (3.36 4.60) 65 29.8 
 
 
 
3rd wave 
(30 – 49 yrs) 
4.06 (3.39 4.87)   
Baseline  
41 – 55 yrs 
4.21 (3.67 4.81) 62 28.4 
3rd wave 
(50 – 64 yrs) 
3.66 (2.99 4.49)   
Baseline 
56-65 yrs 
3.61 (3.17 4.12) 91 41.8 
3rd wave 
(65 – 75 yrs) 
2.44 2.05 2.89   
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Figure 1. Age trend in uBPA concentrations at the Baseline (1998-00) and 3rd wave (2007-09) of the study. 
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 Figure 2. Scatter plot of uBPA Baseline log values against 3rd wave SG adjusted log values, with unadjusted linear regression line: 
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 Table 3. Association between uBPA concentrations and main covariates at Baseline, 3rd wave, and factors associated with changes in uBPA 
concentrations. (a) Linear regression model in 3rd wave was adjusted for SG measurements. In the third column, log(uBPA 3rd wave)-log(uBPA 
Baseline) is the dependent variable, the model is adjusted for age, sex and changes in Income, BMI, Alcohol, Canned Food and Soft Drinks 
consumption. Changes in economic condition were classified as (b) worsened income categorization, and (c) improved income categorization.   
  Baseline (1998-00) 
 Association with log(uBPA) 
 3rd wave (2007-09) a 
Association with log(uBPA) 
 (3rd wave) – (Baseline) 
Association with changes in uBPA 
Variables n beta (95% CI), p-value n beta (95% CI), p-value n beta (95% CI), p-value 
Age 707 -0.008 (-0.012, -0.005) p<0.001 253 -0.009 (-0.016, -0.002) p=0.014 209  
Sex (Male v Female)  -0.093 (-0.199, 0.013) p=0.084  0.006 (-0.178, 0.190) p=0.949  -0.099 (-0.335, 0.137) p=0.409     
Income 
Adequate v Barely adequate 
Adequate v Inadequate 
 
 
 
0.057 (-0.083, 0.198) p=0.425 
-0.048 (-0.184, 0.087) p=0.483 
 
 
 
0.139 (-0.082, 0.359) p=0.217 
0.129 (-0.072, 0.330) p=0.207 
 
 
 
b 0.246 (-0.049, 0.542) p=0.101 
c 0.193 (-0.098, 0.485) p=0.192 
 
BMI  0.006 (-0.005, 0.018) p=0.300  -0.008 (-0.026, 0.011) p=0.408  -0.021 (-0.076, 0.034) p=0.451 
Alcohol (freq drinks per day)  0.074 (0.040, 0.107) p<0.001  0.079 (0.021, 0.137) p=0.008  0.104 (0.011, 0.197) p=0.029 
Canned food (freq per day)  -0.063 (-0.777, 0.650) p=0.862  -0.637 (-2.555, 1.282) p=0.514  1.519 (-0.061, 3.099) p=0.059 
Soft drinks (freq per day)  0.150 (0.013, 0.286) p=0.031  -0.101 (-0.408, 0.205) p=0.516  0.047 (-0.252, 0.346) p=0.756 
R2 (%)  9.8  38.0  15.6 
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 6. Discussion 
In the introduction, I outlined how the study of low chronic BPA exposure is still 
characterised by controversies despite huge scientific efforts. BPA’s endocrine 
disrupting activity has been extensively analyzed in experimental studies and 
pleiotropic mechanisms of BPA action have been described. Yet, this extensive and 
sometimes contradictory body of evidence has not been considered conclusive for 
human risk assessment. Similarly, initial epidemiology investigations have found 
methodological difficulties in the study of human BPA exposure that have been 
discussed in section 1.2.3.  
The aim of this research was therefore to join both an experimental and an observational 
approach in order to answer some of the questions, criticisms and limitations of 
previous studies. 
 
Here, I present the levels of human exposure to BPA measured for the first time in a 
European representative population. These results indicate a widespread BPA exposure 
with levels of detection nearing the totality both at baseline and nine years later, in the 
3rd wave (Chapter 2, 3 and 5). Moreover, accurate uBPA concentrations measured in 24 
hours urine samples were associated with changes in hormones levels, testosterone and 
SBHG, indicating a physiological effect of BPA action (Chapter 2). Further, BPA 
bioactivity was investigated at molecular levels. Evidences from in vivo and in vitro 
studies showed how BPA can modulate the gene expression of the hormone receptors 
ERβ and ERRα (Chapter 3 and 4). Finally, I provide the first results on the exposure to 
BPA in adult subjects analysed over a period of nine years and report on the pattern of 
stability over this time frame (Chapter 5).  
These results are important because, taken together, they suggest that BPA is bioactive 
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 in the human body and suggest possible mechanisms of action both at the molecular and 
physiological level. In addition, this research provides useful indications for the design 
of future epidemiological studies. 
 
 
 
6.1 An integrated approach in the study of Bisphenol A.  
As discussed in section 1.2.3, human exposure to BPA has been recently associated 
with metabolic disorders like obesity, diabetes and, ultimately, with cardiovascular 
disease (CVD). In particular, an increased risk of cardiovascular disease has been 
repeatedly associated in adults with exposure to BPA.  
Epidemiological findings are able to associate level of exposure, uBPA, to a disease 
outcome, CVD, but with no indication on the causal relationship between the two. In 
other words, there is a “black box”, a lack of information on how BPA could cause, at 
biological level, the onset of the disease.  
Four main criticisms have been raised over the plausibility of the association with CVD 
found in the cross-sectional studies (see section 1.2.3). The main criticism has been 
raised because of this black box:  is BPA bioactive at the concentrations measured in the 
human body? What is the molecular mechanism of BPA action in the human body? 
These are clear limitations for standard epidemiology studies. 
In order to answer these questions and move forward in the study of BPA it became 
apparent the need for a more “holistic” approach to the problem. 
A possible way to unravel the black boxes is described by the meet-in-the-middle 
(MITM) principle (Vineis et al. 2013): in order to confirm the plausibility of the link 
between exposure and disease it is fundamental to determine intermediate biomarkers 
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 that could link the two.  
The reasoning is in three steps. The first step of this approach consists in the investigation of the 
association between exposure and disease. The next step consists in the study of the relationship 
between (biomarkers of) exposure and intermediate omics biomarkers of early effects; and 
third, the relation between the disease outcome and intermediate omics biomarkers is assessed. 
The MITM stipulates that the causal nature of an association is reinforced if it is found in all 
three steps (Vineis et al. 2013) . 
This research looked for intermediate biomarkers at different level of biological 
organisation in order to contribute addressing some of the outstanding controversies of 
this field. 
 
6.1.1 Molecular findings. 
As listed in section 1.3 and in Figure 1.2, of particular importance was to study the 
hypothesis that BPA is bioactive in the human body. The expression of ERβ and ERRα 
were both shown to be influenced by exposure to BPA both in in vivo and in vitro 
analyses. The advantages of using an integrated approach were multiple.  
First, ERRα emerged as a novel target of BPA hormone modulating capacity: while 
indications of BPA interaction with ERβ have been extensively reported in animal and 
cell studies (see section 1.2.2), ERRα did not emerge from the literature as a possible 
target of BPA action.  
Second, the validation study, carried out on a human leukemic T-cell line, investigated 
the in vivo hypothesis in laboratory settings where potentially confounding variables 
were controlled. The validation of the original findings using a human blood cell line 
diminishes the possibility that the results in the in vivo study were masked by 
confounding factors. 
Moreover, the identification of ERRα is important not only because its expression is 
highly associated with high levels of uBPA. In fact, ERRα appears to be a promising 
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 intermediate biomarker linked also with metabolic diseases and CVD.  
ERRα activation is modulated by a possible interplay with the transcriptional PPARγ 
co-activator (PGC-1α) (Willy et al. 2004). ERRα has been described as pivotal in 
cardiac functions and adaptation to pressure overload, and is believed to exert protective 
effects against stressors known to cause heart failure (Dufour et al. 2007; Huss et al. 
2007). Also, it has been suggested that the modulation of ERRα and ERRγ activities 
could be used to manage cardiomyopathies (Huss et al. 2007). ERRα is implicated in 
the production and transportation of ATP across the mitochondrial membranes as well 
as Ca2+ handling (Dufour et al. 2007). Interestingly, recent studies have shown that BPA 
can induce arrhythmia in murine models via alteration of Ca2+ handling (Asano et al. 
2010; Yan et al. 2011). 
Moreover, the modulation of the transcriptional circuit ERRα /PGC-1α has been 
suggested as a possible target in therapies for type 2 diabetes (Handschin and Mootha 
2005) as well as having a role in the onset of obesity (Casals-Casas and Desvergne 
2011; vom Saal et al. 2012). These results taken together are indicating a possible 
molecular mechanism of BPA in metabolic disruption.  
 
6.1.2 Physiological  findings. 
In addition to the molecular evidence, this research provides indications also on the 
physiological effects of the exposure to BPA, and in particular on possible changes on 
testosterone blood levels in men.  
This is important because the effect at the physiological level confirms the bioactivity of 
BPA. Moreover, there could be a link between the occurrence of CVD and higher 
testosterone levels. Although just in woman, higher levels of testosterone have been 
linked to increased risk of incident coronary events (Laughlin et al. 2010). In a follow-
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 up study of nearly 13 years, the authors found increased risk of CVD events when total 
and bioavailable testosterone levels were outside an optimal range.  
Furthermore, the association between BPA exposure and testosterone levels could also 
have repercussions on another aspect of the EDC research. In recent years, the so-called 
estrogen hypothesis (Sharpe and Skakkebaek 1993) proposed that the steady decline in 
sperm quality and the high occurrence of male reproductive disorders, such as 
hypospadias, observed in Europe in the last 30-50 years could be due to male exposure 
to estrogen-like compound like BPA.  
More recently, this theory has been expanded to suggest that male in utero exposure to 
oestrogen and anti-androgen compounds could be responsible of several reproductive 
problems that could then lead not only to sperm quality decrease but also to testicular 
cancer (TC) (Skakkebaek et al. 2001). Different studies have shown an increase in the 
incidence of TC in the last 40 years with substantial differences among countries 
(Huyghe et al. 2003). In particular in northern Europe, surprising differences in 
incidence rates were seen between neighbouring countries (Finland 2.5/100,000 cases 
versus Denmark 9.2/100,000). Environmental hypotheses with a key role of endocrine 
disrupters have been put forward in order to explain such a striking geographical 
imbalance.  
Skakkebaek and colleagues hypothesized that TC could originate from primordial germ 
cells with altered differentiation in utero due to exposure to EDC which would also 
result in an impaired testosterone production. These findings confirm the ability of BPA 
to affect the level of testosterone in the male body although more research is needed.    
The link between the findings at the molecular and physiological level is less clear to 
identify. A recent study investigated the effect of BPA on testosterone production in 
Leydig cells (N'Tumba-Byn et al. 2012); the authors suggested that BPA could act 
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 through non-classical estrogen receptors signalling pathway. They suggested that ERRγ 
or an unknown ligand of ERRγ could be responsible of the mechanism of action of BPA 
in regulating testosterone production. 
 
6.1.3 Methodological issues investigated. 
Another controversy that this research investigated is the stability of BPA exposure over 
lengthy periods. Given the results of cross-sectional studies, one of the main criticisms 
of these studies was the lack of indications over the stability of chronic exposure to 
BPA. From a methodological point of view this research is important because we now 
have a better understanding of BPA stability over a long period. Results indicate that a 
single measure of uBPA concentrations showed moderate sensitivity for predicting long 
term exposure (Chapter 5). This adds to the plausibility that reported associations with 
health outcomes may be causal. 
There were other controversies listed in section 1.2.3 regarding (a) the possibility of a 
reverse interpretation of the results, and (b) the risk of misclassification due to the self-
reported diagnoses of cardiovascular disease. These have been widely addressed by a 
recent “nested case-control” epidemiology study (Melzer et al. 2012a) where uBPA 
concentrations were measured nearly 11 years before the participants’ first medical 
diagnose of cardiovascular disease. Given the study design, both (a) and (b) could be 
ruled out as possible explanations for the results.  
 
6.2 Limitations and confounding factors. 
This research presents some limitations that should be considered when interpreting the 
results. In particular, given the contradictory evidence in the literature, the testosterone 
findings need to be replicated in a representative population study. Unfortunately, no 
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 measure of sex hormone concentrations were performed during the 3rd wave of the 
InChianti study so it was not possible to reproduce the same analyses carried out at the 
baseline of the study and reported in chapter 2. 
Moreover, the controversy over the stability of BPA exposure during a significant time 
window cannot be considered resolved. Measurements are still needed to understand the 
value of a single measurement associated to diseases with long latency periods. Ideally, 
the two other follow-ups in the InChianti study (2001-03 and 2004-2006) could provide 
valuable indications and a much more detailed description of BPA stability over nine 
years. Unfortunately, it was not possible to analyze samples from these time-points 
because of costs and practicalities.  
This project focussed on the effect of human environmental exposure to a single 
compound, a single EDC. However, we acknowledge the fact that there is a number of 
compounds to which we are exposed on a daily basis that could have estrogen-like 
properties. The list is long and in continuous expansion. Not only man-made 
compounds, natural estrogens can be found in cow’s milk and meat: modern dairy cows 
are usually pregnant and continue to lactate during the latter half of pregnancy, when 
the concentration of estrogens in blood, and hence in milk, increase (Ganmaa and Sato 
2005). Meat and milk consumption have been linked to hormone induced cancer such as 
ovarian and breast cancer.  
The combined effect of multiple exposures is certainly an issue to consider when 
interpreting the results of this research. A combined exposure could have a confounding 
effect on the study of a single compound, like in this case BPA. It could be argue that 
the confounding effect could operate in two different ways. On the one hand, this could 
cause a form of white noise when measuring the effect of BPA in vivo: exposure to 
natural estrogen, for instance, could make more difficult the detection of a molecular 
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 biomarker of BPA action. For this reason, it was important to test the effect of BPA 
exposure in vitro in order to rule out the effect of any confounder.  
On the other hand, it could be argued that isolating the effect of a single compound from 
a mixture of estrogen-like compound is not possible. In this case, the study of the 
exposure to a single compound can be considered a simpler scenario given the 
complexity of conducting a cumulative risk assessment. However, the risk of BPA 
effects being confounded by the exposure to other estrogen compounds is limited unless 
we consider BPA exposure to be highly correlated with the other compounds.    
 
6.3 Regulation: Politics of Bisphenol A. 
As discussed in the introduction, BPA has been extensively studied in the last 15 years. 
Scientific knowledge has rapidly built and started to reach the public interest until the 
point when in 2008, BPA was making headlines in major national newspapers both in 
the US and Europe. 
In the same year, the Canadian government announced its decision to declare BPA 
toxic. Health Canadian Minister announced Canada's intent to ban the import, sale, and 
advertisement of polycarbonate baby bottles containing Bisphenol A due to safety 
concerns (Vogel 2009). 
From 2009 and 2011 a number of European countries started considering the ban of 
BPA from infant product. In April 2011, the European Union decided that BPA was 
“not to be used for the manufacture of polycarbonate infant feeding bottles” (EU 2011). 
However, public outcry and mounting concern had already pushed retailers and 
producers to meet growing demands for alternatives to BPA-based polycarbonate baby 
and water bottles. BPA-free baby bottle started to appear in the market well before the 
2011. 
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 When in 2012 the US F.D.A. decided to follow a similar path and to ban BPA from 
infant product, manufacturers had already stopped using the chemical and baby bottles 
containing BPA were already out of the market. 
Interestingly, none of these decisions were the result of indications from the US or 
European regulatory agencies. As described in section 1.2.2, the US EPA established in 
1998 the BPA human TDI on the basis of results from carcinogenic studies on rats. It 
quickly became clear how the old paradigms of toxicology and carcinogenic studies 
could not be applied to the study of EDCs.     
Scientists have shown in the last 20 years that a new scientific paradigm should be used 
to define chemical safety. New concepts such as low-dose research and non-monotonic 
dose response are opposing the traditional safety standards based on threshold-dose 
models or high-dose toxicity tests. Low-dose BPA studies explored new endpoints and 
focused on measure of organizational and functional changes as indicators of disease 
risk. They also looked at the relationship between timing of exposure and measured 
effect. 
All these concepts have been cautiously considered by the regulatory agencies who 
were asked to accept a large scientific paradigm shift to carry out the BPA risk 
assessment. As described in section 1.2.3, successive reviews from the US NTP of the 
scientific literature did not found convincing evidence and the TDI was upheld (Chapin 
et al. 2008; Melnick et al. 2002). Yet, many more studies and different endpoint were 
included in the second review and low-dose research is no longer on the margins of 
accepted scientific thought.  
Similarly, the European Food Safety Authority, the EU equivalent of the American 
NTP, was asked to review the epidemiological literature on BPA and CVD (EFSA 
Panel on Food Contact Materials 2010). They concluded that the study design “does not 
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 allow establishment of a causal relationship between BPA exposure and health effects” 
and highlighted the “lack of a common clearly defined mode of action of BPA at low 
doses”. Results from this research may help addressing the question raised by the EFSA 
Panel. 
 
7. Conclusions 
Different indications can be drawn from this research. First of all, analyses from the 
InChianti study confirms the initial hypothesis that BPA is a widespread, ubiquitous 
compound to which virtually all persons in industrialized countries are exposed to. 
Moreover, this research strongly suggests that BPA can be bioactive in the human body 
at environmentally relevant concentrations. This consideration is motivated by 
physiological and molecular findings:  BPA was associated with changes in testosterone 
levels and in estrogenic gene expression targets in men. Further, laboratory evidence has 
confirmed ERRα and ERβ as targets of BPA action in human blood cells. In addition, 
this research provides moderate indication of a long term stability of human BPA 
exposure with measurements from samples collected nine years apart. These results are 
supportive of previous epidemiological findings in which BPA exposure was associated 
with metabolic syndromes. Further studies are needed to understand the potential of 
ERRα modulation to determine the onset of health diseases, in particular examining 
BPA exposure in a wider range of estrogen-regulated target tissues.  
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